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ABSTRACT OF DISSERTATION 
TELOMERASE REVERSE TRANSCRIPTASE IN ATHEROSCLEROSIS  
 
Telomerase reverse transcriptase (TERT) is the catalytic subunit of 
telomerase and the limiting factor for the enzyme activity. The expression of TERT 
and telomerase activity is increased in atherosclerotic plaques. However, the role 
of TERT dysregulation during atherosclerosis formation remains unknown.  
The work herein first identified a multi-tiered regulation of TERT expression 
in smooth muscle cells (SMC) through histone deacetylase (HDAC) inhibition. 
HDAC inhibition induces TERT transcription and promoter activation. At the protein 
level in contrast, HDAC inhibition decreases TERT protein abundance through 
enhanced degradation, which decreases telomerase activity and induces 
senescence. Furthermore, during vascular remodeling in vivo, TERT protein 
expression in the neointima is prevented by HDAC inhibition. These data illustrate 
a differential regulation of TERT transcription and protein stability by HDAC 
inhibition. TERT is highly expressed in replicating SMC of atherosclerotic and 
neointimal lesions. Using a model of guidewire-induced arterial injury, neointima 
formation was reduced in TERT-deficient mice. Studies in SMC isolated from 
TERT-deficient and TERT overexpressing mice with normal telomere length 
established that TERT is necessary and sufficient for cell proliferation. TERT 
deficiency did not induce a senescent phenotype but resulted in G1 arrest albeit 
hyperphosphorylation of the retinoblastoma protein. This proliferative arrest was 
associated with stable silencing of the E2F1-dependent S-phase gene expression 
program which could not be reversed by ectopic overexpression of E2F1. 
Chromatin immunoprecipitation and accessibility assays revealed that TERT was 
recruited to E2F1 target sites to increase chromatin accessibility for E2F1 by 
facilitating the acquisition of permissive histone modifications. These data indicate
a mitogenic effect of TERT on SMC growth and neointima formation through 
epigenetic regulation of proliferative gene expression. Furthermore, TERT 
expression is induced in activated macrophages during experimental and human 
atherosclerosis formation. To investigate the role for TERT in lesional 
macrophages and the subsequent effect on atherosclerosis formation, TERT-
deficient mice were crossbred with LDL-receptor-deficient (LDLr-/-) mice to 
generate first generation G1TERT-/-LDLr-/- offsprings, which were then further 
intercrossed to obtain third generation G3TERT-/-LDLr-/- mice. G1TERT-/-LDLr-/-
mice revealed no telomere shortening while severe telomere attrition was evident 
in G3TERT-/-LDLr-/- mice. When fed an atherogenic diet, G1TERT-/-LDLr-/- and 
G3TERT-/-LDLr-/- mice were both protected from atherosclerosis formation 
compared to their wild-type controls, indicating that genetic TERT-deletion 
prevents atherosclerosis, and formation of the disease is not affected by telomere 
attrition. Similarly, atherosclerosis development was decreased in chimeric LDLr-
/- mice with TERT deletion in hematopoietic stem cells after bone marrow 
transplantation. TERT deficiency reduced macrophage accumulation in 
atherosclerotic lesions and altered chemokine expression, including CXC1/2/3, 
CCL3, CCL5, CCL21, CCR7, IL-6, and IL-1α. In isolated macrophages, gene 
ontology (GO) enrichment analysis of silenced inflammatory genes indicated that 
TERT positively regulates signal transducer and activator of transcription (STAT) 
cascade, which was confirmed by the decreased tyrosine phosphorylation of 
STAT3 protein resulting from TERT deletion. These findings indicate genetic TERT 
deficiency decreases atherosclerosis formation by silencing inflammatory 
chemokine transcription through inactivation of the STAT3 signaling pathway in 
activated macrophages.  
In conclusion, the dysregulation of TERT expression within atherosclerotic 
plaques plays a causative role for vascular remodeling, including injury-induced 
neointima formation and hypercholesterolemia-induced atherosclerosis, through 
inducing SMC proliferation and a pro-inflammatory phenotype in infiltrating 
macrophages. These findings unveil a mechanism of TERT exacerbating the 
pathological vascular remodeling, which may provide a novel therapeutic target to 
combating vascular diseases.   
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1 
1 CHAPTER ONE 
Introduction 
 
1.1 Atherosclerosis 
1.1.1 Introduction 
Atherosclerosis is the most common pathological process leading to 
cardiovascular diseases. Fatty streaks, which can start in childhood, are the initial 
atherosclerotic lesions as a result of macrophage infiltration and foam cell 
accumulation. Fatty streaks seldom cause clinical events but gradually evolve into 
complicated atheromatous plaques with a collection of immune cells, vascular 
smooth muscle cells (VSMC), necrotic cores, calcified regions, modified lipids, and 
foam cells. The chronic expansion of plaques narrows the lumen of the blood 
vessel and eventually causes obstruction, resulting in ischemia of downstream 
tissues. The clinical manifestations as a consequence of insufficient blood supply 
include myocardial infarction, stroke, abdominal aortic aneurysms or lower limb 
ischemia depending on the location of blocked vessel, which determines for a large 
part the extent of morbidity and mortality1. 
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1.1.2 Smooth Muscle Cell Proliferation in Atherosclerosis 
VSMC are primarily distributed in the medial layer of the artery. Disturbed 
laminar flow activates endothelium resulting in increased permeability of 
lipoproteins and inflammatory dysfunction. Under inflammatory stimulation, medial 
VSMC migrate into the intima and undergo dedifferentiation from a quiescent, 
contractile phenotype towards a synthetic, proliferative state that contributes to 
“intimal thickenings”. Therefore, abundant VSMC are found in the intima of specific 
sites with low shear stress that are more susceptible to atherosclerosis formation. 
Compared to the medial VSMC, the intimal VSMC are more  mobile and proliferate, 
and they produce pro-inflammatory mediators that attract other immune cells to 
the site, thus  creating the initial nidus for the development of atherosclerotic 
lesions2.  
Following activation and the subsequent inflammatory response of the 
endothelial cell (EC), VSMC can proliferate under the stimulation of multiple growth 
factors, including platelet-derived growth factor, transforming growth factor-β, 
angiotensin II, epidermal growth factor and insulin-like growth factor 13. These 
various growth factors initiate  signals converging to a cascade of biochemical 
events in the G1 phase of the cell cycle that permit cells to cross the G1/S 
checkpoint  into the S (synthesis) phase. For example, the transition of cells from 
G1 to S phase in the cell cycle requires increased phosphorylation of 
retinoblastoma tumor suppressor protein (Rb). In a hypophosphorylated state, Rb 
sequesters the E2 factor (E2F) family of transcription factors, which are critical 
regulators of G1/S transition, thus activates the transcription of genes encoding 
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the enzymatic and structural machinery for DNA synthesis and chromosomal 
replication. Rb phosphorylation and subsequent E2F release are tightly controlled 
by multiple positive regulators, such as cyclin and cyclin-dependent kinase (CDK) 
complexes, and many negative effectors4. There are two families that prevent the 
progression of the cell cycle, the CIP/KIP (CDK-interacting protein/Kinase 
inhibitory protein) family and the INK4 (Inhibitor of Kinase 4) family. Members of 
both families prevent progression of the cell cycle by inactivating cyclin-CDK 
complexes. However, CIP/KIP inhibitors suppress the entire spectrum of CDKs, 
while INK4 family mainly inhibits CDK4/6 and arrests the cell cycle in the G1 phase. 
The CIP/KIP family includes p21, p27, and p57. p21 is activated by p53, which is 
triggered by DNA damage. The INK4 family includes p15, p16, p18, and p195. 
These positive and negative regulators of cell cycle, as well as their targets, are 
outlined in Figure 1.1. The balance between the positive and negative branches of 
cell cycle regulators is of paramount importance to VSMC proliferation in the 
injured arterial wall and the initiation of atherosclerosis formation.Macrophages in 
Atherosclerosis 
Atherosclerosis is a nonresolving inflammatory condition with continual 
recruitment of circulating monocytes into the intimal atherosclerotic lesions, where 
they differentiate into macrophages and scavenge cholesterol to become foam 
cells. During this process, both the lineage commitment and the functions of 
macrophages in atherosclerotic lesions are also altered. These phenotypic 
alterations of macrophages play important roles at all stages of lesion 
progression6. 
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It has been recognized that macrophages in atherosclerotic plaques 
originate primarily from circulating monocytes instead of local proliferation of 
tissue-resident macrophages7. Monocytes are derived from hematopoietic stem 
cells (HSC), self-renewing stem cells in bone marrow that continuously replenish 
all blood cell lineages.  Differentiation of HSC produces common myeloid 
progenitor cells (CMP) and common lymphocyte progenitor cells (CLP), which 
undergo further differentiations while gradually losing their self-renewing potential 
and give rise to all types of blood cells along multiple lineages. CMP are the 
precursor of granulocytes, macrophage progenitors (GMP), megakaryocyte and 
erythroid progenitors (MEP), and macrophage and dendritic cell progenitors 
(MDP). MDP are the immediate precursor of monocytes, macrophages and 
dendritic cells but not granulocytes. Granulocytes, composed of basophils, 
eosinophils and neutrophils, are derived from GMP8. The entire blood cell 
collection with various flavors all as descendants of HSC (the process is known as 
Hematopoiesis) is illustrated in Figure 1.2. Monocytosis as a result of a series of 
successive proliferation/differentiation events from HSC, and MDP and an 
increase in the number of circulating monocytes, could thus heighten the chance 
of monocytes entering the arterial intima and expedite the development of 
atherosclerosis. There are two subtypes of monocytes, Ly6C+ and Ly6C-9. During 
inflammation, Ly6C+ monocytes infiltrate into the tissue and differentiate into M1 
macrophages, which contribute to tissue degradation and T cell activation and are 
distinguishable from other groups of macrophages by the secretion of pro-
inflammatory cytokines such as TNFa and IL-610. In a steady state, Ly6C+ 
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monocytes differentiate into Ly6C- monocytes, which patrol the lumen through 
crawling on the resting endothelium of blood vessels in healthy tissues. Ly6C- 
monocytes are more likely to mature to M2 macrophages, which secrete anti-
inflammatory cytokines and contribute to tissue repair11.     
Macrophages are the dominant immune cells in atherosclerotic lesions at 
all stages of the disease. The inflammatory macrophage phenotype induced by 
interferon-γ (IFN-γ) and the toll-like receptor 4 (TLR4) ligand lipopolysaccharide 
(LPS) has been classically termed the M1 type. These stimuli initiate a strong 
inflammatory program in the macrophage, which includes production of 
proinflammatory cytokines and chemokines, inducible nitric oxide synthase (NOS) 
producing large quantities of nitric oxide (NO), and production of reactive oxygen 
species to aid in pathogen destruction. An alternative form of macrophages named 
M2 subtype are induced by interleukin-4 (IL-4) and IL-13 and produce proresolving 
molecules, such as IL-10 and transforming growth factor-β. The M2 macrophages 
are involved in tissue remodeling and repair12. However, since the distinctive 
characteristics for classifying the M1 and M2 subtypes are derived from 
experiments in vitro, it is still an open question whether this classification bears 
any significance when applied to in vivo conditions. The phenotype of the lesional 
macrophages, which are exposed to a plethora of stimuli, is more complex as it 
constantly responds to dynamic cues from the microenvironment by intracellular 
signal-relaying cascades and therefore could change with the progression of the 
disease. Nevertheless, the pro-inflammatory macrophages have been shown to 
be the dominant phenotype advanced human endarterectomy lesions, where IFN-
6 
γ is more abundant than IL-413. The inflammatory responses of macrophages are 
the result of an intricate network of signal transductions and gene expressions. For 
example, activation of the TLR pathway triggers nuclear factor kappa-light-chain-
enhancer of activated B cells (NF-κB) and Mitogen-activated protein kinases 
(MAPK) to initiate their respective signaling network, which amplify the original 
signal into the expression of thousands of inflammation-related genes14. 
Therefore, the net proatherogenic effect of lesional macrophages is likely due to 
the highly complex crosstalk between various cytokines and their signaling 
effectors, which can be differentially triggered by a broad spectrum of stimuli. The 
process accompanying proinflammatory macrophage activation mainly includes 
three inflammatory pathways: signal transducer and activator of transcription 
(STAT) molecules activated by IFNγ binding to its receptor, NFκB and MAPK 
triggered by the activation of TLR or tumor necrosis factor (TNF) receptor)15, 16. 
Activation of STAT protein is an essential corresponding downstream effect of 
TLR4 and IFNɣ signaling pathways17. Therefore, the STAT proteins are described 
as central signaling molecules that control cellular adaption and functional 
reprogramming in response to environmental stimuli or stress18. A large number of 
cytokines, growth factors, and hormones function as the ligand to activate STAT 
pathways by binding to their membrane receptors, which subsequently triggers the 
phosphorylation of Janus kinase (JAK). JAK proteins are receptor-associated 
protein tyrosine kinases that activate STAT proteins by tyrosine phosphorylation. 
The STAT proteins are latent transcription factors residing in the cytoplasm which 
translocate to the nucleus when phosphorylated and activate transcription of target 
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genes19. The JAK/STAT signaling pathway is actively involved in regulating 
atherosclerosis formation. Secretion of pro-atherosclerotic cytokines and 
chemokines by macrophages in atherosclerotic lesions, which is a critical 
pathogenic step has been specifically attributed to activation of the IL-6/STAT3 
signaling pathway20-24.   
 
1.2 Telomerase Reverse Transcriptase  
1.2.1 Regulation of Telomerase Reverse Transcriptase 
1.2.1.1 Introduction  
Telomerase reverse transcriptase (TERT) is the catalytic subunit of 
telomerase, which is a ribonucleoprotein that synthesizes telomere repeat 
sequences to protect telomeres from replicative erosion25. TERT is the limiting 
factor for telomerase activity in both cancer and normal somatic cells.  It is critical 
for the maintenance and stabilization of linear chromosomes and the regulation of 
cellular senescence and immortalization26. In the biological system, TERT 
expression is closely regulated in a context-dependent manner via a multi-tiered 
regulatory network involving genetic and epigenetic controls, post-transcriptional 
regulation and post-translational modification27. The transcriptional control is the 
primary and rate-limiting regulation of TERT expression in many cells, for example, 
TERT is transcriptionally repressed in most human somatic cells and is 
upregulated through TERT promoter activation in most cancer cells28. The TERT 
promoter contains binding sites for a number of transcription factors involved in 
cellular proliferation, apoptosis, differentiation, inflammation, and 
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tumorigenesis27, 29. For example, our previous studies have uncovered disease-
relevant/pathogenic VSMC proliferation as a result of TERT up-regulation by 
binding of Ets-1 or E2F1 to the TERT promoter30, 31. Alternative transcript 
splicing of TERT as a result of the post-transcriptional regulation has been 
documented in many human tissues and cell lines, and likely plays a role in the 
regulation of telomerase activity and other cellular functions by TERT. The human 
TERT gene contains 16 exons and can be spliced into multiple isoforms. None of 
the identified alternatively spliced forms of TERT gene has reverse transcriptase 
activity, thus they cannot reactivate telomerase and elongate telomeres. Although 
it is assumed that most variants are degraded and unlikely translated into proteins, 
some TERT isoforms have been shown to be potentially oncogenic32. The 
observation that the abundance of TERT protein does not translate into telomerase 
activity leads to the discovery of post-translational modifications, e.g., the 
phosphorylation of specific serine, threonine, or tyrosine residues, as an important 
regulatory mechanism for TERT activity. These phosphorylation events facilitate 
TERT nuclear translocation thereby allowing for assembly of active telomerase to 
elongate telomeres33.   
 
1.2.1.2. Epigenetic Regulation of TERT Expression 
Among the multilayered control of TERT expression and function described 
above, the chromatin environment and epigenetic status of the endogenous TERT 
locus are also pivotal for the regulation of TERT mRNA level. Epigenetic regulation 
of TERT expression is mainly achieved through tagging of the histone core 
9 
complexes and methylation of the CpG loci near the promoter region34. In 
eukaryotes, genomic DNA is wrapped around histone octamers each composed 
of two tetramers of H2A, H2B, H3 and H4 subunits to form structural units known 
as nucleosomes, which can be further condensed into higher-order chromosomal 
architectures. Such tightly bundled configuration blocks the access of promoters 
and regulatory elements on the DNA by transcription-associated factors and the 
transcriptional machinery. To allow dynamic access to condensed DNA, chromatin 
and nucleosomes can be dynamically restructured in a process called chromatin 
remodeling, in which various covalent labels are added to or removed from the 
histone proteins that signal to the ATP-powered remodeling complexes which 
actually perform the restructuring35. The N-terminal tails of the histones are subject 
to a variety of covalent modifications including acetylation, methylation, 
phosphorylation, and ubiquitination36. Histone hyperacetylation, which can be 
enhanced by unchecked activity of histone acetyltransferase (HAT), marks active 
transcription due to the uncoiling of DNA and histones. On the other hand, removal 
of these acetyl groups by histone deacetylases (HDAC) reduces accessibility of 
the modified regions by allowing the chromatin to acquire a more compact 
conformation36. HDAC can be inhibited by a class of competitive inhibitors, which 
facilitates stable histone acetylation resulting in enhanced nucleosomal 
unwrapping and activates gene transcription within chromatin regions that are 
otherwise heavily condensed37. In human somatic cells that are terminally 
differentiated, the TERT gene locus lies within a compact, nuclease-resistant 
chromatin domain and remains inactive.  The fact that HDAC inhibitors can 
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increase TERT transcription, as shown in multiple studies, suggests that native 
chromatin environment, i.e., formation of heterochromatins, is critical for the tight 
regulation of TERT during cell proliferation and differentiation38-41.    
 
1.2.2 Function of TERT  
1.2.2.1 Telomeric Functions of TERT 
Because of the “end replication problem”, the failure of the DNA replication 
machinery to replicate the end of linear chromosomes, chromatin erosion at the 
termini occurs in each round of DNA replication cycles in eukaryotic organisms. 
Telomeres, the repetitive DNA-protein complexes at the end of chromosomes, not 
only act as a buffer to counteract replication-associated shortening, but also 
conceal linear chromosome ends from being falsely identified as strand breaks and 
subject to inappropriate repair which usually results in detrimental chromosomal 
fusions42. Over time telomeres become critically shortened with successive cell 
divisions, which triggers replicative senescence, a status in which cells 
permanently exit cell cycle. As a result, normal somatic cells can only proliferate 
for a limited number of times/generations predetermined by their telomere length, 
the molecular basis for cellular senescence and normal human aging43. 
Telomerase is an enzyme that maintains the integrity of telomeres by adding 
telomeric repeats to chromosome ends. Telomerase is composed of a catalytic 
subunit TERT, an RNA-containing subunit and associated proteins. The 
telomerase RNA serves as the template for reverse transcription by TERT25. In 
humans, telomerase is ubiquitously expressed during the first weeks of 
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embryogenesis, after which it is generally repressed throughout embryonic 
development and remains inactive in normal somatic human cells, while in 
activated lymphocytes, germ line cells, stem cells, and cancer cells, the enzyme 
activity is maintained44. Although TERT transcription is undetectable in matured 
somatic cells, its level is elevated during telomerase reactivation. Furthermore, 
telomerase activity can be fully restored by ectopic expression of TERT. Therefore, 
TERT is recognized as the most important limiting subunit for telomerase activity26. 
Transcriptional regulation of TERT expression is suggested to be the dominant 
regulatory mechanism for the silencing of telomerase during cellular differentiation 
as well as its reactivation during carcinogenesis27. Moreover, TERT-deficient mice 
exhibit significantly telomere erosion and phenotypes associated with telomere 
shortening, such as the loss of tissue renewal, in late generations of the TERT-
deficient lineage obtained by successive cross-breeding of heterozygous TERT-
deficient mice45. Thus, TERT is necessary and crucial for telomerase activity and 
the maintenance of telomere integrity.   
 
1.2.2.2 Non-Telomeric Functions of TERT 
In addition to telomere elongation, accumulating evidence indicates that 
TERT also has fundamental functions that are independent of its enzymatic 
activity. These non-telomeric functions of TERT are broadly associated with the 
regulation of gene expression, modulation of cellular signaling, cell cycle 
regulation, reducing reactive oxygen species release, protection of mitochondria, 
inhibition of apoptosis, promotion of cellular and organismal survival, and 
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modulation of DNA damage response46-48. In addition, TERT was found to shuttle 
between different cellular compartments where specific localization can change 
under a variety of conditions, such as during the progression through different cell-
cycle stages, cellular transformation and when the cells suffer from extensive DNA 
damage49. This observation further reinforces the notion of telomere-independent 
functions of TERT involved in different cell signaling pathways when targeted to 
different locations or responding to different stimulations.  
Among these telomere-independent activities of TERT, the role of TERT in 
gene transcription has been investigated in detail. Experiments of global 
expression profiling or single specific gene analysis have shown that TERT affects 
the expression of hundreds of genes, which involve in diverse cellular processes 
including growth control, energy metabolism, apoptosis, DNA damage response, 
wound healing, tumor metastasis and angiogenesis50-56. Similarly, our previous 
study also identified an extra-telomeric role of TERT in macrophage expression of 
matrix metalloproteinase-2 (MMP-2) during abdominal aortic aneurysm 
formation57. To date, how TERT is involved in gene transcription is largely 
unknown. It has been suggested that TERT may function as transcription effector 
to recruit other transcription factors. For example, TERT interacts directly with the 
nuclear factor NF-kB p65 subunit to stimulate inflammatory gene expressions58. 
More emerging evidence indicates that TERT participates in the modulation of 
chromatin architecture. For example, TERT alters histone tail modification and 
chromatin in cells lacking TERT is more susceptible to micrococcal nuclease 
digestion59. TERT also interacts with transcription activator BRG1, which is a 
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component of ATP-dependent chromatin remodeling complexes and has helicase 
and ATPase activities. The interaction between TERT and BRG1 regulates the 
expression of genes involved in the Wnt signaling pathway and contributes to 
heterochromatin assembly at locations distinct from telomeres60. These findings 
imply novel molecular mechanisms of TERT in many essential cellular processes 
by targeting genes and pathways beyond its well defined function in telomere 
biology. 
In summary, the canonical function of TERT is telomere elongation as a 
component of telomerase. However, accumulating evidence indicates various non-
telomeric functions of TERT, including regulating the expression of a broad 
spectrum of genes. As a transcription regulator, TERT may be present in different 
protein complexes and play essential parts in modulating chromatin structures 
(Figure 1.3). However, the mechanisms by which TERT controls gene transcription 
remain controversial and require further investigation. 
1.2.3 Telomere and Telomerase Homeostasis in Atherosclerosis 
1.2.3.1 Introduction 
Telomere attrition serves as a key checkpoint in the control of cell 
proliferation by triggering replicative senescence. Therefore, telomere-based 
senescence has been closely implicated in cancer development and aging44. 
Telomerase activity and TERT expression are upregulated in most cancer cells in 
support of unrestrained cellular proliferation. On the other hand, lack 
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of telomerase activity in human somatic tissues and concomitant telomere erosion 
correlates with age-related pathologies61, 62. Telomere-associated gene mutations, 
e.g. TERT or TERC, result in accelerated telomere shortening, which is the cause
of three human disorders, dyskeratosis congenita63, multiple different diseases 
collectively characterized by bone marrow failure64, and idiopathic pulmonary 
fibrosis65. Their clinical presentation is associated with an impaired proliferative 
capacity of cells in tissues requiring constant renewal, i.e. skin, oral mucosa and 
bone marrow, indicating the capacity to maintain adequate telomere length is vital 
for tissues with high proliferative potential. Telomerase reactivation by 
overexpressing TERT in cancer-resistant mice extends lifespan, supporting the 
hypothesis that repressed telomerase supports cancer resistance at the cost of 
longevity66. Conversely, this trade-off for cancer resistance increases the risk for 
age-related degenerative diseases67. Generally, telomeres erode with age, and 
reflect a cell’s past proliferative history and future propensity for apoptosis, 
senescence, and transformation. However, it remains controversial whether 
telomere shortening contributes to the aging process and aging-related diseases, 
including atherosclerosis68. Moreover, contrary to the general concept of the aging-
associated telomere attrition, telomeres are actually elongated in the 
atherosclerotic plaques, a result of increased TERT expression and activated 
telomerase, the extent of which correlates with the severity grade of 
atherosclerosis69-71. Therefore, during the pathogenesis of specifically 
atherosclerosis formation, telomeres may change differently in peripheral blood 
leukocytes and cells within local tissues. Also, together with elongated telomeres, 
15 
the upregulated TERT expression and reactivated telomerase within the arterial 
intima suggest a functional involvement of the telomeric system in vascular 
remodeling.   
 
1.2.3.2 Telomere and Telomerase Homeostasis in Endothelial Cells 
 Aging is a major risk factor for the initiation and the development of 
atherosclerosis. There is growing evidence about telomere biology and cell 
senescence involved in the pathogenesis of cardiovascular diseases. Telomere 
shortening in EC was observed during atherosclerosis formation, which is 
considered to be caused by oxidative stress as a consequence of the disturbed 
blood flow72. Meanwhile, EC in human atherosclerotic lesions present a 
senescence-associated phenotype which can be rescued by ectopic expression of 
TERT using viral transduction73. Chronic oxidative stress and diminished activation 
of PI3K/AKT pathway may be the underlying mechanism bridging telomeric 
aberrations and loss of EC viability74. However, until now there is little proof to 
show a direct effect of TERT on stress-induced premature senescence of EC 
during atherosclerosis formation. 
  
1.2.3.3 Telomere and Telomerase Homeostasis in Smooth Muscle Cells 
The differentiation and maturation of human somatic cells occur with the 
suppression of TERT expression and telomerase activity. As telomeres shortens 
with each replication cycle, these cells gradually lose replicative competency and 
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permanently exit cell cycle43. However, accumulating evidence suggests that 
during tissue renewal and healing processes, expression of TERT can be induced 
in response to various environmental cues, which enhances cell multiplication in 
the time of need27. Similarly, inducible expression of TERT has been shown in 
proliferating SMC during neointima and atherosclerosis formation30, 31. Multiple 
mechanistic models that link the activation of telomerase and proliferation of VSMC 
have been proposed. Minamino et al. demonstrated that TERT activation through 
phosphorylation and the subsequent nuclear translocation accounts for 
telomerase-driven cell life span75. In addition, our previous study has identified that 
TERT is the key factor that mediates the restenosis-preventing effect of 
everolimus, which coats the stent and limits tissue overgrowth. SMC proliferation 
is dependent on the expression of TERT which facilitates E2F1 binding to S-phase 
gene promoters76.  
VSMC within human atherosclerotic plaques displays a senescence 
phenotype with a limited proliferative capacity77. These cells present low level of 
TERT expression and short telomeres78, indicating that a TERT-associated 
premature cellular senescence phenotype may participate in the pathogenesis of 
human atherosclerosis. 
 
1.2.3.4 Telomere and Telomerase Homeostasis in Inflammation 
Age-associated immune deficiency is considered a major contributory factor 
to the increased frequency of morbidity and mortality among the elderly. Adaptive 
immunity of ageing individuals deteriorates because of a progressive decline of 
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global T cell and B cell populations, possibly as a consequence of the exhaustion 
of the available pools of naïve lymphocytes and along with their predecessors. The 
innate immunity of aging individuals, however, is relatively well preserved although 
age-dependent alterations are frequently observed79. Inflammation plays a crucial 
role for the development of atherosclerosis. The presence of short LTL in human 
atherosclerosis can be mainly attributed to increased leukocyte turnover during 
inflammation and the following accelerated telomere loss per replication80. 
Similarly, telomere shortening in T lymphocytes and accelerated leukocyte 
turnover are evident in patients with chronic infection and inflammatory disease81, 
82. Therefore, telomere shortening is considered to be a feature of 
immunosenescence characterized by a decreased ability to produce antibodies, 
the decline in phagocytosis and cellular migration, as well as a reduction of cell 
numbers83. Although atherosclerosis is an age-related disease, telomere erosion 
in mice shows an atheroprotective effect. The late generation TERC-knockout 
mice on an apolipoprotein E-deficient background developed fewer 
atherosclerotic lesions, which has been associated with an impaired proliferative 
capacity of macrophages and lymphocytes84. Therefore, telomere attrition might 
cause cellular senescence, and apoptosis in difference cell types, but have 
variable effects on complex disease processes in a tissue-specific pattern.  
Immune cells are unique among normal somatic cells as the activated 
phenotype can up-regulate telomerase and limit telomere attrition in the process 
of continued cell proliferation. Telomerase activity and TERT expression in 
immune cells have been demonstrated to be elevated during viral or bacterial 
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infection, as well as in a variety of chronic diseases related with low-grade 
inflammation, including atherosclerosis, idiopathic pulmonary fibrosis, rheumatoid 
arthritis, and systemic lupus erythematosus85. Consistent with the dysregulation of 
TERT and telomerase in both acute and chronic scenarios of inflammation, 
telomerase activity and TERT expression have been shown to regulate the 
secretion of inflammatory cytokines58, 86-89.  
Considering these collectively findings described above, TERT protein 
expression and telomerase activity are inducible in various cell types circulating 
in the vessel and telomere shortening in genetic models may impact vascular 
dysfunction. However, whether TERT deficiency and loss of telomerase activity 
play a causal role in vascular remodeling and atherosclerosis formation is 
incompletely understood.   
 
1.3 Hypothesis and Specific Aims  
The cellular mechanisms underlying vascular remodeling during 
atherosclerosis formation include endothelial cell activation and subsequent 
macrophage infiltration. Among the many proteins and enzymes implicated in 
tissue repair, telomerase is recognized as one of the most important proteins 
involved in remodeling processes. However, its role in inflammation and vascular 
disease remains unknown. Our recent studies have confirmed an increased 
expression of TERT in atherosclerosis and after vascular injury30, 31, 71, 32, 72. TERT 
is highly induced by mitogenetic and atherogenic stimulation in SMC and 
macrophages. However, the role of TERT dysregulation within the arterial intima 
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and the consequence of inducible vascular TERT overexpression in the process 
of vascular remodeling remains unknown.  
 
Aim One: TERT transcription is dependent on chromatin remodeling, and HDAC 
inhibition prevents atherosclerosis formation and neointima formation. Therefore, 
the first aim is to define whether and how pharmacological HDAC inhibition targets 
TERT expression during proliferative vascular remodeling.  
 
Aim Two: Aberrant proliferation of VSMC in response to injury induces 
pathological vascular remodeling during atherosclerosis and neointima formation. 
Telomerase is the rate-limiting factor for cell replication and tissue renewal whose 
physiological roles in vascular diseases remains to be determined. Therefore, the 
second aim is to determine whether TERT affects proliferative vascular remodeling 
and to identify the molecular mechanism of TERT-driven VSMC proliferation. 
 
Aim Three: TERT is highly induced by atherogenic lipoproteins and inflammatory 
cytokines in macrophages. Thus, we will continue to investigate the function of 
TERT overexpression in macrophages during atherosclerosis formation. The third 
aim is to define the role and mechanisms of TERT in macrophage activation and 
the consequent development of atherosclerosis.
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Figure 1.1 The Regulation of Cell Cycle. 
Cyclins and cyclin-dependent kinase (CDK) complexes are the positive 
regulators to drive cell cycle forward. Conversely, the INK4 family (p15, p16, 
p18, and p19) and CIP/KIP family (p21, p27, and p57) are the main inhibitors to 
inactivate cyclin-CDK complexes and halt the progression of the cell cycle. 
Besides, P53, triggered by DNA damage, is another negative master to stop the 
cell cycle by promoting P21 production. p14 prevents the degradation of p53, 
thus links to the p53/p21 pathway to inhibit cell-cycle progression. 
21 
 
Figure 1.2 Development to Macrophages from Hematopoietic Stem Cells. 
The figure illustrates the differentiation pathways of hematopoietic stem cells 
(HSC) that give rise to the various hematopoietic cell lineages. CLP, common 
lymphoid progenitors; CMP, common myeloid progenitors; GMP, granulocyte 
and macrophage progenitors; MDP, macrophage and dendritic cell progenitors; 
MEP, megakaryocyte and erythroid progenitors; DC, dendritic cell; NK, natural 
killer. 
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Figure 1.3 Functions of Telomerase Reverse Transcriptase 
The canonical function of telomerase reverse transcriptase (TERT) is the 
maintenance of telomere integrity. Alternatively, TERT may function as a 
transcription cofactor or participate in chromatin remodeling, thus playing a role 
in the regulation of gene expression. The genes that might be regulated by TERT 
are involved in many essential cellular functions and biological processes, such 
as cell growth, DNA damage response, apoptosis, inflammation, angiogenesis, 
and metastasis. These extra-telomeric functions of TERT may play an important 
part in tumorigenesis. In addition, under oxidative stress, TERT translocates 
from nucleus to mitochondria, which could modify mitochondrial functions such 
as its metabolic capacity, energy efficiency and reactive oxygen species (ROS) 
production by the electron transferring complexes. 
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2 CHAPTER TWO 
Differential Regulation of Telomerase Reverse Transcriptase 
Promoter Activation and Protein Degradation by Histone Deacetylase 
Inhibition 
 
2.1 Abstract 
Telomerase reverse transcriptase (TERT) maintains telomeres and is rate 
limiting for replicative life span. While most somatic tissues silence TERT 
transcription resulting in telomere shortening, cells derived from cancer or 
cardiovascular diseases express TERT and activate telomerase. In the present 
study, we demonstrate that histone deacetylase (HDAC) inhibition induces TERT 
transcription and promoter activation. At the protein level in contrast, HDAC 
inhibition decreases TERT protein abundance through enhanced degradation, 
which decreases telomerase activity and induces senescence. Finally, we 
demonstrate that HDAC inhibition decreases TERT expression during vascular 
remodeling in vivo. These data illustrate a differential regulation of TERT 
transcription and protein stability by HDAC inhibition and suggest that TERT may 
constitute an important target for the anti-proliferative efficacy of HDAC inhibitors.  
 
2.2 Introduction 
Telomeres are repetitive DNA sequences which protect the ends of 
chromosomes and are maintained by the catalytic activity of telomerase reverse 
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transcriptase (TERT)90. Since most adult somatic cells transcriptionally repress 
TERT, telomeres shorten progressively during tissue renewal91. This telomere 
shortening has been suggested to limit the replicative potential and ultimately 
induce cellular senescence92. Conversely, TERT expression is induced and 
telomerase is activated during cancer and atherosclerosis development, both 
being the most prevalent human diseases70, 71, 93. The observation that TERT 
overexpression induces cancer formation94, 95 and provides an unlimited mitotic 
potential96 has suggested a permissive role for TERT to sustain cancer cell 
proliferation. Consequently, there has been significant interest to develop targeted 
TERT therapeutic approaches, which are currently being tested in clinical trials97.  
While a critical contribution of TERT to oncogenesis has been well-
described, its role in atherosclerosis and neointima formation remains unknown.  
TERT expression and telomerase activity are induced during atherosclerosis 
formation and in response to vascular injury30, 70, 71. At the cellular level, mitogenic 
stimulation induces TERT transcription and telomerase activity in vascular smooth 
muscle cells (VSMC) 98. In vitro, this transient expression of TERT is both 
necessary and sufficient for the proliferation of VSMC30, 31, pointing to an important 
function of TERT for the proliferative response underlying vascular disease. 
Because TERT transcription is dependent on chromatin remodeling99, we 
investigated in the present study whether inhibition of histone deacetylation 
induces TERT transcription. Furthermore, since histone deacetylase (HDAC) 
inhibition prevents atherosclerosis formation and neointima formation100, 101, we 
evaluated whether pharmacological HDAC inhibition targets TERT expression 
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during proliferative vascular remodeling. We provide direct evidence that inhibition 
of histone deacetylation activates TERT transcription but decreases its protein 
stability, ultimately resulting in repression of telomerase activity and senescence, 
mechanisms that likely contribute to the inhibition of neointima formation by HDAC 
inhibitors.  
 
2.3 Materials and Methods 
Cell Culture 
Rat aortic vascular smooth muscle cells (VSMC) were purchased from 
Lonza and maintained in DMEM supplemented with 10% FBS. Cells were starved 
in serum-free DMEM for 24 hours, pretreated with Scriptaid (Enzo Life Sciences) 
at the indicated doses for 30 min and stimulated with 10% FBS for the indicated 
time points. For protein stability assays, 10 µg/ml cycloheximide (Sigma) was 
added to cell cultures to inhibit protein synthesis, and cytosolic and nuclear 
proteins were harvested subsequently at the indicated time points. 
 
Quantitative Real-time RT-PCR  
 Total RNA was isolated with TRIzol® (Invitrogen) and reverse transcribed 
into cDNA using SuperScript II (Invitrogen). RNA expression of target genes was 
quantified using an iQTM SYBR Green Supermix (BioRad). Primers used in this 
study are as follows: TERT, forward:  5’-GTACAGCTGCTGAGGTCATTCTT-3’; 
reverse: 5’-AAACACTGGGTCTGCTTCTTTTT-3’; P16, forward: 5’-
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GGTCACCGACAGGCATAACTTC-3’; reverse: 5’-
AAAGGAGGGCTGAGGCCTAA-3’; P21, forward: 5’-
CCGGGAGAACATGTATTTTGGT-3’; reverse: 5’-
GGGTGTAAAGATTCGGGACAGT-3’; GADD45, forward: 5’-
TGGTGACGAACCCACATTCA-3’; reverse: 5’-ACTGGCACCCACTGATCCAT-3’; 
RPL3A, forward: 5’-GTACGCTGTGAGGGCATCAA-3’; reverse: 5’-
CTCGAGACGGGTTGGTGTTC-3’. Samples were analyzed in triplicate and 
normalized to expression values of the housekeeping gene RPL3A. Data were 
calculated using the 2-CT method102. 
 
HDAC siRNA Transfection  
siRNA experiments were performed using the SMARTpool technology 
(Dharmacon RNA Technologies), which provides a mix of four different proprietary 
siRNAs specific for the target gene. VSMC were transfected with HDAC1, HDAC2, 
HDAC3 or scrambled siRNA (50 nM) using LipofectamineTM RNAiMAX (Invitrogen) 
for 6 hours. Following transfection, cells were recovered in growth media overnight, 
serum-deprived for 24 hours and stimulated with growth media for 24 hours before 
collecting RNA.  
 
Plasmids, Transient Transfections and Luciferase Assays 
The TERT promoter constructs have been described previously31. VSMC 
were transiently transfected with 1.0 µg TERT promoter construct using 
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Lipofectamine 2000 (Invitrogen) in OPTI-MEM. Following transfection, cells were 
serum deprived, treated with 6 µM Scriptaid and stimulated with complete growth 
media for 24 hours. Luciferase activities were analyzed using a Dual Luciferase 
Reporter Assay (Promega). Transfection efficiency was normalized to Renilla 
luciferase activities generated by cotransfection of pRL-null-renilla. 
 
Western Blotting 
Cytosolic and nuclear fractions were isolated using a Nuclear and 
Cytoplasmic Extraction Kit (Thermo Scientific) and protein was subjected to routine 
immunoblotting using the following antibodies: TERT (Rockland 600-401-252S), 
TBP (Abcam ab818) and GAPDH (Sigma G9545). Expression of GAPDH and TBP 
was used to assess for equal protein loading for cytosolic and nuclear 
compartments, respectively. 
 
Telomerase Activity Analysis 
Telomerase activity was measured using a quantitative Telomerase 
Detection Kit (Allied Biotech Inc.) per manufacturer’s instructions. Telomerase 
activity was quantified by real-time PCR using whole-cell extract containing 0.5 µg 
of protein.  
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Senescence Analysis 
VSMC were treated with Scriptaid at the indicated doses for 48 hours and stained 
overnight for β-galactosidase activity using a Senescent Cell Histochemical 
Staining Kit (Sigma CS0030) according to the manufacturer’s instructions. 
Endovascular Femoral Artery Guide Wire Injury 
Guide wire endothelial denudation injuries were performed in C57BL/6J 
mice (The Jackson Laboratory) at 8 weeks of age as described30. Twelve mice 
were injected with Scriptaid or DMSO the day before injury, on the day of the injury, 
and every other day thereafter for 28 days. The dose of Scriptaid (3.5 µg/g body 
weight intraperitoneally) used in this study was based on the doses used in our 
previous Scriptaid study101. All procedures on mice were approved by the 
institutional animal care and use committee at the University of Kentucky. 
2.4 Results 
2.4.1 TERT Transcription Is Induced by HDAC Inhibition 
To first evaluate whether histone acetylation affects TERT transcription, we 
employed the HDAC inhibitor Scriptaid, which potently suppresses histone 
deacetylation in vascular cells and inhibits VSMC proliferation101, 104. As depicted 
in Figure 2.1 A-B, pre-treatment of VSMC with previously published doses of the 
HDAC inhibitor Scriptaid induced TERT mRNA expression in a time- and dose-
dependent manner105. At the employed doses and kinetics Scriptaid did not induce 
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apoptosis, as assessed by Annexin V and propidium iodide staining (data not 
shown). In order to establish specificity of this pharmacological approach and to 
identify specific HDAC that regulate TERT mRNA expression, we next employed 
siRNA-knockdown of HDAC1, 2 and 3 in VSMC. Depletion of HDAC1, but not 
HDAC2 or HDAC3, significantly increased TERT transcript levels (Figure 2.1 C). 
To further evaluate the mechanism by which HDAC inhibition regulates TERT 
transcription, we next analyzed TERT promoter activity in Scriptaid-treated VSMC. 
Transient transfection of a luciferase reporter driven by the full-length TERT 
promoter revealed a solid induction of TERT promoter activity in response to 
HDAC inhibition by Scriptaid (Figure 2.1 D). Collectively, these findings confirm 
that pharmacological HDAC inhibition and HDAC1 depletion induce TERT 
transcription in VSMC.   
2.4.2 HDAC Inhibition Decreases TERT Protein Levels and Suppresses 
Telomerase Activity 
We next analyzed whether the induction of TERT transcription by HDAC 
inhibition translated into increased TERT protein expression levels. However, 
surprisingly Scriptaid treatment potently decreased both nuclear (Figure 2.2 A) and 
cytoplasmic (Figure 2.2 B) TERT protein levels in a dose-dependent fashion. Since 
TERT is the limiting factor for telomerase activity, we further analyzed whether 
HDAC inhibition reduced the enzymatic activity of TERT. Consistent with the noted 
decline in TERT protein mass, inhibition of HDAC activity by Scriptaid significantly 
attenuated telomerase activity in VSMC (Figure 2.2 C). Albeit inducing TERT 
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transcription, these observations indicate that HDAC inhibition ultimately 
decreases TERT protein mass resulting in a decline of telomerase activity. 
2.4.3 HDAC Inhibition Accelerates TERT Protein Degradation 
Since Scriptaid decreased both nuclear and cytoplasmic TERT expression, 
we reasoned that HDAC inhibition might decrease protein stability rather than 
enhance nuclear export. Consistent with this notion, HDAC inhibitors have been 
previously reported to trigger protein degradation106. To address this question, we 
pretreated VSMC with vehicle or Scriptaid and performed a chase experiment after 
inhibiting protein de novo synthesis with cycloheximide. As depicted in Figure 2.3, 
Scriptaid treatment significantly decreased TERT protein stability compared to 
vehicle treatment. Therefore, HDAC inhibition may destabilize TERT protein 
through post-translational modifications, an effect that ultimately prevails over 
increased transcription induced by histone acetylation.  
2.4.4 HDAC Inhibition Induces VSMC Senescence 
Depletion of telomerase activity induces telomere shortening and replicative 
senescence92. Therefore, we next investigated whether the depletion of TERT 
induced by HDAC inhibition resulted in cellular senescence. As expected and 
depicted in Figure 2.4 A, Scriptaid treatment of VSMC induced β-galactosidase 
expression, a well-established biomarker of senescence107. Furthermore, Scriptaid 
treatment induced a gene expression program implicated in cellular senescence, 
including transcript levels of p16, p21 and GADD45 (Figure 2.4 B). In concert, 
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these experiments demonstrate that the decline in telomerase activity induced by 
HDAC inhibition is associated with VSMC senescence.  
2.4.5 HDAC Inhibition Reduces TERT Expression in Neointima Following 
Vascular Injury 
Pharmacological HDAC inhibitors suppress cell proliferation108, and in our 
previous studies we demonstrated that HDAC inhibition by Scriptaid attenuates the 
proliferative response underlying pathological neointima formation101. Based on 
our in vitro data, we hypothesized that HDAC inhibition might suppress TERT 
expression in vivo during pathological neointima formation in response to vascular 
injury. To address this question, we analyzed TERT expression in femoral arteries 
of mice treated either with vehicle (DMSO) or Scriptaid and subjected to vascular 
injury using a model of endothelial denudation injury101. As depicted in Figure 2.5 
A, nuclear TERT expression was highly induced during neointima formation. In 
contrast, the inhibition of neointima formation by the HDAC inhibitor was 
associated with significantly decreased vascular TERT expression, even after 
normalization for the reduced neointimal area (Figure 2.5 B). This finding 
establishes that TERT expression in the neointima is suppressed by HDAC 
inhibition, which may contribute to the prevention of neointimal VSMC proliferation 
observed with HDAC inhibition.   
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2.5 Discussion 
Inhibition of histone deacetylation through pharmacological approaches is 
currently being evaluated in clinical trials as a novel promising anti-proliferative 
therapy109. During vascular remodeling, HDAC inhibitors potently prevent 
neointima formation and inhibit aberrant VSMC proliferation101. Although 
telomerase activation constitutes a key mechanism implicated in the replicative 
potential of a cell91-93, the regulation of TERT by HDAC inhibition and its 
importance as pharmacological target for the anti-mitotic efficacy of HDAC 
inhibitors in vascular cell types have previously not been evaluated. In the present 
study, we demonstrate that both pharmacological inhibition and genetic depletion 
of HDAC activate TERT transcription. However, TERT protein levels and 
telomerase activity are potently inhibited by HDAC inhibition due to accelerated 
protein degradation. This inhibition of TERT expression results in cellular 
senescence, an effect that likely contributes to the anti-proliferative efficacy of 
HDAC inhibitors during neointima formation in response to vascular injury.  
TERT constitutes the limiting factor for the catalytic activity of telomerase110. 
While TERT expression is inherently associated with aberrant cell proliferation93, 
most normal somatic cells epigenetically silence TERT promoter activity by DNA 
methylation and histone deacetylation111, 112. However, during the activation of 
malignant cell proliferation, transcription factors sequester HDAC from the TERT 
promoter allowing subsequent histone acetylation and transcription from the 
promoter113. Similarly as during cancer formation, aberrant VSMC proliferation 
constitutes a hallmark of atherosclerosis development and neointimal remodeling2. 
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During this proliferative process, VSMC transcriptionally induce TERT expression 
and telomerase activity, which are required for their mitotic response30, 31. To our 
knowledge, data presented here are the first to establish that inhibition of HDAC 
activity or HDAC1 depletion activates TERT transcription in VSMC. Our 
observation that TERT promoter activation is induced by HDAC inhibition is 
consistent with several prior studies38, 39, 111. Furthermore, siRNA-mediated knock-
down confirmed specificity for HDAC1 in the repression of TERT transcription in 
VSMC. Conversely, overexpression of HDAC1 has been reported to lead to the 
repression of the TERT promoter in cancer cells39. However, the regulation of 
TERT by histone deacetylation remains controversial, since TERT transcription 
has also been reported to be repressed by pharmacological HDAC inhibitors40, 114. 
Therefore, the mechanisms underlying TERT transcription are likely dependent on 
the environmental cues and specific for various tissues.  
Although Scriptaid treatment of VSMC activated the promoter, TERT activity 
was reduced and TERT protein degradation enhanced by HDAC inhibition. In 
addition to activating transcription by histone tail modification, HDAC inhibitors are 
well-established to induce post-translational modification, including protein 
degradation through ubiquitination115, 116. Moreover, while TERT expression is 
primarily regulated at the transcriptional level, posttranslational modification and 
proteasome-mediated degradation of TERT have been reported to play an 
important role for telomerase inactivation117, 118. In support of a differential 
regulation of TERT transcript levels and protein abundance by HDAC inhibition is 
a recent study in glioma cells that reported decreased TERT activity albeit 
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increased TERT transcription in response to HDAC inhibition119. The molecular 
mechanism underlying enhanced TERT protein degradation by HDAC inhibition is 
likely indirect through increased lysine acetylation of non-histone proteins, thereby 
regulating protein stability. One reasonable hypothesis supported by the literature 
for future investigation may involve increased acetylation of the TERT chaperone 
HSP90 by HDAC inhibition120, an effect that would result in enhanced protein 
degradation of its well-established client TERT117.  
HDAC inhibitors target TERT expression in cancer cells40, 121 and have 
recently provided promising results in phase II clinical trials122, 123; however, their 
efficacy in human vascular disease remains unknown. In preclinical models, HDAC 
targeting stabilizes atherosclerosis and prevents proliferative remodeling during 
neointima formation following endovascular injury100, 101. In this study, we extend 
these observations and demonstrate that HDAC inhibition downregulates TERT 
expression during neointima formation in vivo. Specific targeting of telomerase 
activity in a rat model of vascular injury has recently been demonstrated to prevent 
neointima formation124. Furthermore, TERT depletion is well-established to inhibit 
VSMC proliferation and induce cellular senescence30, 31, consistent with our 
observation that Scriptaid-dependent downregulation of TERT protein abundance 
increased beta-galactosidase staining and senescence-associated gene 
expression. Therefore, although the inhibition of VSMC proliferation and neointima 
formation by Scriptaid in our previous studies likely involves targeting of multiple 
mitogenic proteins101, TERT repression may play an important role for the anti-
proliferative efficacy of HDAC inhibitors.  
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Figure 2.1 HDAC Inhibition Induces TERT Transcription. 
A-B, Scriptaid increases TERT mRNA expression in a dose- (A) and time-
dependent (B) manner. TERT mRNA expression levels was analyzed by 
quantitative real-time RT-PCR and normalized to transcript levels of the 
housekeeping gene RPL3A. Values are mean ± SEM (* P < 0.05 vs. DMSO 
treatment). C, HDAC1 siRNA increases TERT mRNA expression. VSMC were 
transfected with siRNA targeting HDAC1, 2 and 3, or Scrambled siRNA control. 
Values are mean ± SEM (* P < 0.05 vs. scrambled siRNA). D, Scriptaid activates 
the TERT promoter. VSMC were treated with 6 µM Scriptaid or DMSO after 
transfection with a TERT promoter construct driving a luciferase reporter. 
Transfection efficiency was adjusted by normalizing firefly luciferase activities to 
Renilla luciferase activities generated by cotransfection with pRL-CMV. Values 
are mean ± SEM (* P < 0.05 vs. DMSO). 
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Figure 2.2 HDAC Inhibition Decreases TERT Protein Levels and 
Telomerase Activity. 
A-B, Scriptaid down-regulates TERT protein expression. TERT protein 
expression levels were analyzed by Western blotting in nuclear (A) and 
cytoplasmic (B) fractions harvested after 24 hours of Scriptaid or DMSO 
treatment. Cohybridization for TBP or GAPDH was performed to control for equal 
protein loading. The autoradiographs shown are representative of 3 
independently performed experiments. C. Scriptaid decreases telomerase 
activity in VSMC. Telomerase activity was analyzed 48 hours after 3 µM 
Scriptaid or DMSO treatment. Values are mean ± SEM (* P < 0.05 vs. DMSO).    
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Figure 2.3 HDAC Inhibition Accelerates TERT Protein Degradation. 
After Scriptaid or DMSO pre-treatment, cycloheximide (CHX 10µg/ml) was 
added to inhibit protein synthesis and whole cell lysates were harvested at the 
indicated time points. The autoradiographs shown are representative of 3 
independently performed experiments. 
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Figure 2.4 HDAC Inhibition Induces VSMC Senescence. 
A, Scriptaid enhances senescence-associated β-galactosidase activity. 
Serum-deprived VSMC were pretreated with Scriptaid or DMSO at the 
indicated doses for 30 minutes, and then stimulated with 10% FBS for 48 
hours. Scale bars, 100 µM. B, Scriptaid induces senescence-associated 
gene expression. mRNA was harvested 24 hours after 6 µM Scriptaid or 
DMSO treatment. P16, P21, and GADD45 mRNA expression levels were 
analyzed by quantitative real-time PCR and normalized to transcript levels 
of the housekeeping gene RPL3A. Values are mean ± SEM (* P < 0.05 vs. 
DMSO treatment).   
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Figure 2.5 HDAC Inhibition Reduces TERT Expression in the 
Neointima Following Vascular Injury. 
A, Representative TERT staining in the neointima after vascular injury. 
Tissues were stained for TERT (red) and nuclei counterstained with 
hematoxylin (blue). Scale bars, 100 µM. B, Quantification of TERT-positive 
cells in the neointima. The percentage of TERT-positive cells to the 
neointima area was calculated as the amount of TERT-positive cells 
divided by the neointima area. Cross sections with the same distance from 
sutures were examined (n= 3 per group). Values are mean ± SEM (* P < 
0.05 vs. DMSO treatment).   
 
40 
3 CHAPTER THREE 
Telomerase Reverse Transcriptase Deficiency Prevents 
Neointima Formation 
 Through Chromatin Silencing of E2F1 Target Genes 
3.1 Abstract 
Objective: Aberrant proliferation of smooth muscle cells (SMC) in response to 
injury induces pathological vascular remodeling during atherosclerosis and 
neointima formation. Telomerase is rate limiting for tissue renewal and cell 
replication; however, the physiological role of telomerase in vascular diseases 
remains to be determined. The goal of the present study was to determine whether 
telomerase reverse transcriptase (TERT) affects proliferative vascular remodeling 
and to define the molecular mechanism by which TERT supports SMC 
proliferation.  
Approach and Results: We first demonstrate high levels of TERT expression in 
replicating SMC of atherosclerotic and neointimal lesions. Using a model of guide-
wire induced arterial injury, we demonstrate decreased neointima formation in 
TERT-deficient mice. Studies in SMC isolated from TERT-deficient and TERT 
overexpressing mice with normal telomere length established that TERT is 
necessary and sufficient for cell proliferation. TERT-deficiency did not induce a 
senescent phenotype but resulted in G1 arrest albeit hyperphosphorylation of the 
retinoblastoma protein. This proliferative arrest was associated with stable 
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silencing of the E2F1-dependent S phase gene expression program and not 
reversed by ectopic overexpression of E2F1. Finally, chromatin 
immunoprecipitation and accessibility assays revealed that TERT is recruited to 
E2F1 target sites and promotes chromatin accessibility for E2F1 by facilitating the 
acquisition of permissive histone modifications.  
Conclusions: These data indicate a previously unrecognized role for TERT in 
neointima formation through epigenetic regulation of proliferative gene expression 
in SMC. 
3.2 Introduction 
Telomerase has been implicated in multiple developmental processes 
including cell activation, differentiation, proliferation, and apoptosis43. The catalytic 
activity of telomerase maintains telomeres, hexanucleotide DNA-protein 
complexes that protect the ends of chromosomes, and is rate-limiting for tissue 
renewal125. Since most somatic cells repress the telomerase reverse transcriptase 
(TERT) catalytic core, telomeres shorten progressively during tissue renewal 
ultimately limiting lifespan91. In addition to the extension of telomeres, mounting 
evidence suggests that TERT exhibits a direct regulatory role in the activation of 
gene expression without apparent involvement of its well-established function in 
telomere homeostasis126. Early profiling experiments first documented that TERT 
induces differential gene expression55. More recent support for a non-canonical 
activity of TERT derives from the observation that TERT induces cell proliferation 
independently of its catalytic activity and function to elongate telomeres55, 94, 127-129. 
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Although the mechanisms underlying this non-canonical, mitogenic function of 
TERT remain elusive, TERT has been demonstrated to activate specific 
transcriptional programs and associates with chromatin at locations distant to 
telomeres, indicating a possible function of TERT in the epigenetic control of gene 
expression60, 130. 
Aberrant cell proliferation constitutes an important mechanism underlying 
proliferative vascular remodeling during atherosclerosis and neointima formation2. 
Although telomerase is recognized as one of the most ancestral proteins in the 
control of mammalian cell proliferation, it remains to be investigated whether TERT 
causally contributes to these cardiovascular diseases. TERT expression is low in 
quiescent SMC of the normal vasculature71, 78, but increased during neointima 
formation and atherosclerosis development30, 70, 71. In cultured cells, TERT is 
induced in both activated macrophages and in proliferating SMC30, 70, 71, 98. In SMC, 
the transient increase in TERT abundance in response to growth factor stimulation 
serves a mitogenic role since inhibition of TERT by oligonucleotide or 
pharmacological targeting inhibits SMC proliferation30, 31, 70, 75, 98, 131. Furthermore, 
acute telomerase downregulation using TERT antisense RNA decreases 
proliferation of SMC isolated from genetically hypertensive rats132. Although recent 
genetic experiments established that the mitogenic activity of TERT requires 
neither telomere extension nor the catalytic activity55, 127-129, the molecular 
mechanisms by which TERT supports cellular proliferation remain elusive.   
In this study, we employed a genetic model of TERT-deficiency to 
investigate the transcriptional mechanisms underlying the mitogenic activity of 
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TERT during proliferative vascular remodeling. Our studies reveal that TERT 
deletion prevents neointima formation and SMC proliferation by inducing a 
silenced chromatin environment at S phase gene promoters.  
3.3 Materials and Methods 
Immunohistochemical Staining 
For immunohistochemical staining of TERT expression in human coronary 
atherosclerotic lesions, segments of coronary arteries were harvested from 
explanted hearts during cardiac transplantation as described71. Tissues were fixed 
in 4% phosphatebuffered formaldehyde and embedded in paraffin, and transverse 
sections (8 μm) were collected. Serial paraffin-embedded sections were incubated 
with a mouse monoclonal TERT antibody (ab5181, Abcam) or mouse monoclonal 
anti-smooth muscle α-actin antibody (ab18147, Abcam) followed by biotinylated 
goat anti-mouse IgG (BA-9200, Vector Laboratories) and counterstaining with 
hematoxylin. For immunofluorescent colocalization studies, tissues were 
incubated with antibodies raised against TERT (GTX82476, GeneTex), PCNA 
(ab2426, abcam) and a-SMA (ab7817, abcam), followed by incubation with Alexa 
Fluor 647-conjugated goat anti-chicken, Alexa Fluor 488-conjugated goat anti-
mouse, and Alexa Fluor 594-conjugated goat anti-rabbit antibodies (A-21449, 
A11001 & A11012, Invitrogen) and counterstaining with DAPI. Using a similar 
protocol, paraffin-embedded sections of mouse femoral arteries subjected to guide 
wire-induced injury or sham surgery were stained with PCNA (ab18197, abcam) 
or TERT (MA5-16034, Thermo) followed by incubation with Alexa Fluor 488-
44 
conjugated goat anti-mouse and Alexa Fluor 594-conjugated goat anti-rabbit 
antibodies (A11001 & A11012, Invitrogen) and counterstaining with DAPI. 
Cell Culture 
Primary human coronary artery SMC and growth media were commercially 
obtained (Lonza) and cultured per the manufacturer’s instructions. Primary murine 
aortic vascular SMC were isolated from mice as described. TERT-/- mice were 
obtained from The Jackson Laboratory (TERT-/- mice133, stock number 005423, 
The Jackson Laboratory) and maintained using heterozygote parental breeders57. 
SMC were isolated from the first generation offspring littermate G1TERT+/+ and 
G1TERT-/- mice. To obtain third generation G3TERT-/- offsprings, G1TERT-/- 
mice were interbreed using cousin mating strategies. Mice overexpressing a 
murine TERT transgene (referred to as TERTtransgenic) under control of the 
ubiquitin C promoter were kindly provided by Drs. Richard Hodes and Jeffrey 
Chiang133. Mice hemizygous for this transgene were interbred with C57BL/6J mice 
obtained from the Jackson Laboratory (C57BL/6J, Stock number 000664, The 
Jackson Laboratory) to generate littermate TERT wildtype mice (referred to as 
TERTwildtype). For all cell culture experiments, cells passage three to nine were 
used. Cells were grown to 60-70% confluence and serum deprived in 0.4% FBS 
(Invitrogen) for at least 24 hours, followed by stimulation with 10% FBS for the 
indicated time. All human and animal studies were performed with the approval of 
the University of Kentucky, Institutional Review Board or Institutional Animal Care 
and Use Committee, respectively. 
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TERT siRNA Transfection 
siRNA experiments were performed using the SMARTpool technology 
(Dharmacon RNA Technologies), which provides a mix of four different proprietary 
siRNAs specific for human TERT. Human coronary artery SMC were transfected 
with TERT or scrambled siRNA (50 nM) using LipofectamineTM RNAiMAX 
(Invitrogen) for 6 hours. 
Adenoviral Infection 
Human coronary artery SMC, or G1TERT+/+ and G1TERT-/- SMC were 
transduced with the indicated plaque-forming units (PFU)/cell of adenovirus 
overexpressing GFP (Adx-GFP), TERT (Adx-TERT/GFP), or E2F1 (Adx-E2F1). 
Transduction efficiency was verified at > 90% using fluorescence microscopy and 
Western Blotting. For 5-bromodeosyuridine incorporation (BrdU) assays, SMC 
were incubated with BrdU reagent for 12 hours after 24-hours of adenoviral 
infection. 
Proliferation Assays 
For all proliferation assays, cells were serum-deprived for 24 hours and 
stimulated with 10% FBS for 48 hours. SMC proliferation was analyzed by cell 
counting using a hemocytometer. BrdU assays (Millipore) were performed per 
manufacturer’s instructions. For analysis of cell cycle distribution, cells were 
trypsinized, fixed in ice cold 70% ethanol, treated with 40 μg/mL RNase (in PBS) 
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for 30 minutes at 37°C, and labeled with 50 μg/mL propidium iodide (in PBS). Cell 
cycle distribution was determined using a FACSCalibur sorting system (Becton 
Dickinson). For all data shown, individual experiments were performed at a 
minimum in triplicate using different preparations of cells. 
Endovascular Femoral Artery Guidewire Injury 
Guidewire-induced endothelial denudation injuries were performed on the 
left femoral artery of littermate G1TERT+/+ and G1TERT-/- mice (n=8/group) at 8-
12 weeks of age with a 0.25-mm SilverSpeed-10 hydrophilic guidewire (Micro 
Therapeutics Inc, Irvine, Calif) as described134. The denudation injury was 
accomplished with 4 passages of the wire. Mice were euthanized 28 days after 
injury, and femoral arteries were isolated and embedded in paraffin for tissue 
analysis. Sections were stained with an elastic Verhoeffvan Gieson staining kit 
(Sigma Aldrich) to visualize the internal and external elastic lamina. The intimal 
and medial areas were measured by computerized morphometry using Image-Pro 
Plus 7.0 software (MediaCybernetics) as described134. 
Western Blotting 
Western blotting was performed as previously described134 using the 
following antibodies: Phospho-Rb (Ser807/811) (9308, Cell Signaling), MCM7 (sc-
9966, Santa Cruz Biotechnology), Acetyl-Histone H3 (Lys9) (9469, Cell Signaling), 
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TERT (600-401-252, Rockland), E2F1 (05-379, Upstate), CBP (7389, Cell 
Signaling) and GAPDH (sc-25778, Santa Cruz Biotechnology). 
Quantitative RT-PCR 
RNA isolation and quantitative real-time RT-PCR analyses were performed 
as recently described. Primer sequences are listed in Table I. mRNA expression 
levels were analyzed in triplicate and normalized to housekeeping genes TFIIB 
(murine) or TBP (human). For quantitative real-time RT-PCR analyses, data were 
calculated using the 2-ΔΔCt method102. 
Immunoprecipitation 
Human coronary artery SMC extracts were immunoprecipitated overnight 
with 2 µg rabbit IgG (2729, Cell Signaling), anti-TERT (600-401-252, Rockland), 
or anti-E2F1 (sc-193, Santa Cruz), followed by 4 hours incubation with protein A 
agarose beads (9863, Cell Signaling). The protein A-antigen-antibody complexes 
were washed five times with 1 x cell lysis buffer, resuspended with 3x SDS sample 
buffer, and heated at 100°C for 5min. Samples were then analyzed by Western 
Immunoblotting with indicated antibodies. 
TERT shRNA Lentiviral Transduction 
SMARTvector human lentiviral TERT shRNA (5548171, GE Dharmocon) 
was employed to deplete TERT expression (referred to as shTERT). SMARTvector 
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empty vector control (S-005000-01, GE Dharmocon) was used as negative control 
(referred to as shCTL). Human coronary artery SMC were infected with lentivirus 
at an MOI of 5 for 24 hours. Infection efficiency was verified at >90% after 48 hours 
infection by mRNA quantification using real-time PCR. 
Chromatin Immunoprecipitation Assays 
SMC were stimulated with FBS for 10 hours following 24 hours of serum-
deprived starvation. Cells were then collected for Chromatin Immunoprecipitation 
(ChIP) assays using the MAGnify Chromatin Immunoprecipitation System 
(Invitrogen) according to manufacturer’s instructions. 50μg of chromatin was 
immunoprecipitated with 5μg of antibody raised against E2F1 (sc-193x, Santa 
Cruz Biotechnology), TERT (582000, Calbiochem), Acetyl-Histone H3 (Lys9) 
(9649, Cell Signaling) or CBP (7389, Cell Signaling). Rabbit polyclonal IgG 
(Invitrogen) was used as a negative control. Immunoprecipitated DNA was 
amplified by quantitative RT-PCR using SYBR green. Primers used for quantitative 
PCR amplify nucleotides -346 to -176bp of the murine MCM7 promoter, -356 to -
102bp of the murine cyclin A promoter, -305 to -97bp of the murine PCNA 
promoter, -355 to -190bp of the human MCM7 promoter, -250 to -100bp of the 
human cyclin A promoter, and -547 to -700bp of the human PCNA. In addition, 
primers targeting loci upstream of E2F1 binding sites were used as negative 
controls. Primer sequences are listed in Table I. 
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Chromatin Accessibility by Real-Time PCR (ChART-PCR) 
G1TERT+/+ and G1TERT-/- SMC were serum-deprived and stimulated with 
FBS for 12 hours. Following stimulation, nuclei were harvested using the protocol 
described by Rao et al. 135and digested using Cac8I restriction enzyme (New 
England BioLabs). Digested DNA was purified using the QIAquick Gel Extraction 
Kit (QIAGEN) per manufacturer’s instructions. 20ng of recovered DNA was 
analyzed by quantitative PCR using SYBR green. Primers used amplify 
nucleotides -346 to -176bp of the murine MCM7 promoter and encompass two 
E2F1 binding sites and three Cac8I restriction sites. Decreased PCR amplification 
of this sequence indicates Cac8I digestion and increased chromatin accessibility. 
Results were normalized using primers which amplify upstream sequences - 620 
to -513bp of the murine MCM7 promoter lacking Cac8I restriction sites (listed in 
Table I) and expressed as percent accessibility. 
Telomere Length Analysis 
For quantification of telomere length using real-time PCR, samples were 
run in triplicate with 35 ng of DNA per reaction using an iCycler and SYBR Green 
I system (Bio-Rad) as described. Telomere repeat copy number data were 
normalized to 36B4 as single-copy gene. The primer sequences are listed in Table 
I.
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Senescent Staining 
Murine SMC were seeded at a density of 8x105 cells per well on a 6-well 
plate and serum-deprived in DMEM containing 0.4% FBS. After 24 hours, 
senescent staining was performed as previously described using the Senescent 
Cells Histochemical Staining Kit (Sigma Aldrich). 
Statistical Analysis 
To compare two groups on a continuous response variable, we used a 2-
sample Student t test or Mann–Whitney U test as appropriate. One-way ANOVA 
was used to compare multiple groups, followed by Tukey post hoc analysis. All 
data are presented as mean ± SEM. 
3.4 Results 
3.4.1 TERT Is Expressed in Replicating Neointimal Smooth Muscle Cells 
TERT protein expression was first analyzed in neointimal SMC of human 
coronary artery atherosclerotic lesions from hearts explanted during cardiac 
transplantation. While TERT expression is considered negligible in normal 
arteries71, 78, we confirmed abundant TERT expression in the SMC-rich neointimal 
region of the fibroatheroma (Figure 3.1 A). Furthermore, confocal microscopy 
confirmed that TERT expression colocalizes with proliferating cell nuclear antigen 
(PCNA), a cofactor of DNA polymerase required for replication (Figure 3.1 B). 
Similarly, TERT was highly expressed in replicating SMC during the proliferative 
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response following vascular injury of the mouse femoral artery (Figure 3.1 C). 
Therefore, this upregulation of TERT expression may indicate an important role in 
vascular remodeling underlying neointima formation. 
3.4.2 TERT Is Required for Smooth Muscle Cell Proliferation and 
Neointima Formation 
Inhibition of TERT has previously been shown to inhibit SMC proliferation75,
98, 131. Using siRNA-mediated TERT knock-down and adenoviral-mediated 
overexpression of TERT (Appendices Figure A.1A-C), we corroborated that TERT 
is both necessary and sufficient for SMC proliferation (Figure 3.2 A-B). To advance 
these studies to in vivo models, we next isolated primary aortic SMC from TERT-
deficient and TERT overexpressing mice133. Consistent with the well-described 
phenotype26, 136-138, the first generation G1TERT-/- progeny from heterozygote 
founder mice exhibits normal telomere length (Appendices Figure A.2) and none 
of the phenotypes associated with telomere attrition. However, homozygous 
intercrossing of G1TERT-/- mice results in progressive telomere loss in third 
generation G3TERT-/- mice (Appendices Figure A.2). To further complement this 
genetic TERT depletion model, we studied proliferation of SMC isolated from 
C57BL/6 mice overexpressing a murine TERT transgene under control of the 
ubiquitin C promoter (referred to as TERTtransgenic)133. When exponentially 
growing aortic SMC from these mice were analyzed (Figure 3.2 C), cells isolated 
from hemizygous TERTtransgenic mice displayed a marked growth advantage 
compared to their littermate controls (referred to as TERTwildtype). Conversely, 
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SMC isolated from G1TERT-/- mice exhibited a complete growth arrest compared 
to G1TERT+/+ cells. Interestingly, the growth arrest occurred to a similar extent in 
G1 and G3TERT-/- SMC, indicating that this mitogenic defect is primarily due to 
TERT deletion and does not require telomere attrition. To further corroborate that 
the mitogenic arrest is due to TERT deficiency, we overexpressed TERT in 
G1TERT-/- SMC, which rescued proliferation (Figure 3.2 D). Based on these data 
and to investigate the regulation of SMC proliferation by TERT in vivo, we next 
analyzed the proliferative response underlying neointima formation in G1TERT-/- 
mice. As depicted in Figure 3.3 A and B, neointima formation was significantly 
decreased in G1TERT-/- mice compared to their wildtype G1TERT+/+ littermates. 
Collectively, these results indicate that TERT deletion decreases SMC proliferation 
in vitro and during neointima formation in vivo. 
3.4.3 TERT Deletion Induces Cell Cycle Arrest and Silences E2F1 Target 
Gene Expression 
We next sought to identify the mechanisms responsible for the growth arrest 
of G1TERT-/- SMC. Using real-time PCR for sensitive quantification of telomere 
lengths, we first confirmed that G1TERT-/- SMC did not display measurable 
evidence of telomere attrition (Appendices Figure A.2). Furthermore, TERT 
deficiency did not induce senescence-associated β-galactosidase staining or gene 
expression (Appendices Figure A.3 A-B). From these data we inferred that the 
growth arrest induced by TERT-deficiency was likely independent of the well-
established function of TERT to extend telomeres and prevent cellular 
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senescence. Therefore, we next analyzed DNA synthesis and cell cycle 
distribution. These studies revealed that TERT deficiency inhibited mitogen-
induced DNA synthesis (Figure 3.4 A) and arrested SMC in the G0/G1 phase of the 
cell cycle to reduce S phase entry (Figure 3.4 B-C). This transition from G1 → S 
phase is mediated through phosphorylation of the retinoblastoma protein (Rb)139. 
However, TERT depletion did not result in decreased Rb phosphorylation but 
rather hyperphosphorylation (Figure 3.4 D-E), indicating that TERT deletion alters 
DNA synthesis likely through a mechanism downstream of Rb phosphorylation.  
Rb phosphorylation releases the transcription factor E2F1, which 
transactivates promoters required for S phase entry and ensuing DNA replication,  
including the bona fide E2F1 target genes cyclin A, PCNA, and minichromosome 
maintenance proteins (MCM)140, 141. Although Rb was hyperphosphorylated in 
G1TERT-deficient cells, downstream expression of these three E2F1 target genes 
was silenced (Figure 3.4 F). This differential S phase gene expression profile 
occurred in the absence of changes in E2F1 expression levels (Appendices Figure 
A.4). Similarly, other activating E2F family members were not affected by deletion
of the TERT locus (Appendices Figure A.3.B). To further complement this finding, 
we employed siRNA-mediated knockdown of TERT in primary human coronary 
artery SMC. As depicted in Figure 3.4 G-I, the induction of MCM7 mRNA and 
protein expression in response to mitogenic stimulation was attenuated in TERT-
depleted SMC. Complementary data was obtained for the E2F1 target genes cyclin 
A and PCNA (data not shown).  
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3.4.4 TERT Is Recruited to Chromatin and Required for E2F1 Binding to 
Canonical Sites 
The silencing of E2F1 target gene expression in TERT-deficient SMC 
indicated that TERT might facilitate E2F1-dependent transcription. To assess this 
possibility, we first confirmed that E2F1 and TERT physically associate in human 
coronary artery SMC (Figure 3.5 A). However, to more directly test whether TERT 
is recruited to canonical E2F1 motifs, we performed chromatin 
immunoprecipitation (ChIP) assays using primer pairs that cover the E2F1 sites in 
the cyclin A, PCNA, and MCM7 promoters. As shown in Figure 3.5 B, mitogenic 
stimulation of G1TERT+/+ SMC induced not only E2F1 binding to its target site in 
the MCM7 promoter but also a potent and inducible co-recruitment of TERT. 
Further evaluation of the chromatin complex demonstrated that this recruitment of 
E2F1 and TERT was associated with increased acetylation of histone H3 (K9Ac-
H3), a typical chromatin modification of gene activation142. To investigate whether 
TERT is required for E2F1 binding to chromatin and to validate the role of TERT 
in the regulation of E2F1-dependent transcription, we next analyzed whether TERT 
deficiency affects E2F1 recruitment to its response elements within the MCM7, 
Cyclin A, and PCNA promoters. As depicted in Figure 3.5 C, inducible TERT 
binding to E2F1 canonical sites in the MCM7 promoter was negligible in human 
coronary artery SMC depleted of TERT using a lentiviral approach (Appendices 
Figure A.1 D). Similarly, no TERT binding was observed at upstream non-
canonical promoter regions (Appendices Figure A.6), confirming specificity of the 
ChIP assay. Comparable results were observed for the cyclin A and PCNA 
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promoters (data not shown). As further shown in Figure 3.5 D-F, this mitogen-
induced E2F1 recruitment to the MCM7, cyclin A, and PCNA promoters was 
significantly reduced upon TERT depletion. A complementary impairment of E2F1 
binding to its target sites was observed in G1TERT-/- murine cells (data not 
shown). These studies confirm that TERT supports E2F1 binding to its target sites 
within promoters of genes required for entry into S-phase of the cell cycle.  
3.4.5 TERT-Deficiency Decreases Chromatin Accessibility and Histone 
Acetylation 
We next examined chromatin accessibility specifically at E2F1 binding sites 
using a Chromatin accessibility by Real-Time PCR (ChART-PCR) assay135. Briefly, 
this highly sensitive assay to quantify chromatin accessibility combines DNase 
hypersensitivity with specific restriction enzyme digestion followed by PCR 
amplification, thereby providing a quantitative chromatin accessibility assessment 
at a specific transcription factor binding site. Genomic DNA from G1TERT-/- and 
G1TERT+/+ SMC was subjected to DNase I, meningococcal nuclease, and Cac8I 
restriction enzyme digestion followed by real-time PCR using primers 
encompassing the E2F1 motif in the MCM7 promoter (Figure 3.6 A). The restriction 
enzyme Cac8I specifically cleaves the E2F1 motif TTTCGCGC, and accessible 
euchromatin will not be amplified by PCR since the primers cannot hybridize to the 
E2F1 site due to cleavage by the restriction enzyme. As shown in Figure 3.6 B, 
TERT-deficiency was associated with significantly reduced chromatin accessibility 
at the E2F1 site relative to G1TERT+/+ SMC. Since our data established that 
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TERT occupancy of E2F1 sites is associated with the enrichment of histone H3 
acetylation, we further analyzed whether TERT-deficiency modulates the 
recruitment of permissive histone acetylation at E2F1 sites. As shown in Figure 3.6 
C, FBS stimulation of human coronary artery SMC resulted in a profound increase 
in lysine 9 histone H3 acetylation of the E2F1 response elements within the MCM7 
promoters. In contrast, this inducible histone acetylation was completely abolished 
in human coronary artery SMC transduced with TERT shRNA lentivirus. Similarly, 
mitogen-induced lysine 9 histone H3 acetylation was reduced at the protein level 
in G1TERT-/- SMC (Figure 3.6 D-E), a finding that may at least in part contribute 
to the silenced chromatin state at E2F1 sites in TERT-deficient cells. Considering 
that the p300/CREB-binding protein (CBP) coactivator family confers histone 
acetyltransferase activity41 that is required for E2F1 activation of its S phase target 
genes42, we investigated whether CBP contributes to histone H3 acetylation during 
TERT-dependent E2F1 recruitment. A direct TERT-CBP interaction was first 
confirmed by immunoprecipitation (Figure 3.6 F). Furthermore, mitogen-induced 
CBP recruitment to E2F1 target chromatin within the MCM7 promoter was 
confirmed by ChIP. In contrast, inducible CBP recruitment was markedly impaired 
upon TERT deletion (Figure 3.6 G). Decreased H3 acetylation and altered CBP 
recruitment upon TERT depletion were also observed at the cyclin A and PCNA 
(data not shown). These findings suggest that TERT facilitates CBP recruitment 
and subsequent Histone H3 acetylation to disrupt repressive chromatin at E2F1 
target chromatin.  
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To finally corroborate decreased chromatin accessibility as a possible 
mechanism underlying silencing of E2F1 target genes, we overexpressed E2F1 in 
G1TERT-/- SMC. A silenced chromatin state accompanying TERT deficiency 
should produce a permanent insensitivity to E2F1-dependent proliferation, since 
E2F1 would be unable to access its consensus sites. As depicted in Figure 3.6 H-
J, adenoviral-mediated transduction of E2F1 (Appendices Figure A.5) in SMC 
wildtype for the TERT locus increased expression of its target gene MCM7 
expression and the ensuing cell proliferation and DNA synthesis. In contrast, this 
activity of ectopic E2F1 to induce target gene transcription and cell proliferation 
was altered in TERT-deficient SMC. Collectively, these experiments identify TERT 
as a component of the chromatin complex at E2F1 sites and establish a previously 
unrecognized role for TERT to activate E2F1-dependent gene promoters through 
chromatin modulation.  
3.5 Discussion 
Altered SMC function constitutes a pivotal component of pathological 
vascular remodeling and neointima formation2, 143. In the present study, we 
illustrate a previously unrecognized mechanism that supports the mitogenic 
phenotype of SMC. The inducible expression of TERT in proliferating SMC during 
vascular remodeling and the requirement for SMC proliferation in vitro and 
neointima formation in vivo establish an important role for TERT in vascular 
biology. TERT is required for the activation of an S phase gene expression 
program, associates with chromatin at E2F1 consensus sites, and facilitates the 
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acquisition of a permissive chromatin environment through CBP-mediated histone 
acetylation. Collectively, these experiments support a novel role for TERT in the 
epigenetic control of SMC proliferation. 
While expression of the catalytic subunit of telomerase TERT is considered 
to be negligible in the normal vasculature71, 78, we observed that TERT is induced 
in proliferating SMC during the neointimal remodeling process resulting from 
atherosclerosis formation or vascular injury. Using loss and gain-of-function 
approaches combined with genetic TERT modulation in mice, our data 
demonstrate a causal relationship between TERT expression and the mitogenic 
response. Similarly, prior studies using oligonucleotide or pharmacological 
targeting of TERT documented decreased SMC proliferation75, 98, 131. To extend 
these observations, we studied SMC proliferation in primary cells isolated from 
G1TERT-deficient mice in vitro and neointima formation in vivo in mice deficient 
for the TERT locus. This murine model has been widely employed to exploit 
telomere-independent functions of TERT in G1TERT-/- mice with normal telomere 
lengths as well as phenotypes that occur as a result of progressive telomere 
attrition in third generation G3TERT-/- mice131, 144-147. Conversely, constitutive 
expression of TERT in transgenic mice does not elongate telomeres136 since TERT 
only elongates critically short telomeres57, 148. Therefore, this transgenic model 
provides another means to study TERT activities that occur independently of its 
function to extend telomeres94, 127-129. In our experiments, TERT-deficiency in the 
presence of normal telomere length in G1TERT-/- mice induced growth arrest of 
SMC and reduced neointima formation. In contrast, TERT overexpression in SMC 
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isolated from transgenic mice elicited a clear growth advantage. From these 
observations we infer that the SMC growth arrest induced by TERT deficiency 
does not depend on telomere attrition but rather on TERT function. Consistent with 
this notion is the accumulating evidence that TERT induces, for example, stem cell 
and cancer proliferation through telomere-independent mechanisms that do not 
require the catalytic activity94, 127-130. Furthermore, proliferating cancer cells 
express splice variants deficient in catalytic activity, and expression of these 
variants in telomerase-negative cells induces cell proliferation149, pointing to a 
novel non-canonical function of TERT in the regulation of cell proliferation. 
G1TERT-deficient SMC did not display senescence-associated changes in 
their phenotype or gene expression, further supporting a telomere-independent 
mechanism of growth arrest. Instead, cell cycle analysis revealed that TERT-
deficiency induced a G1S phase arrest associated with decreased DNA 
synthesis. Similarly, acute knock-down of TERT in cancer cells induces cell cycle 
arrest without telomere shortening while TERT overexpression drives epithelial 
cells into S phase150, 151. In proliferating cells, phosphorylation of the Rb protein 
constitutes a critical first step for S phase entry139, which in turn releases its active 
transcriptional repression of E2F1139, 141. In TERT-deficient SMC we observed 
hyperphosphorylation of Rb, which would be expected to release E2F1-dependent 
repression, induce target gene transcription, and facilitate S phase entry. Contrary 
to this assumption, mitotic E2F1 target genes required for DNA synthesis were 
silenced in TERT-deficient SMC, albeit increased Rb phosphorylation. This 
unanticipated requirement of TERT for E2F1-dependent transcription was neither 
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the result of decreased E2F1 protein expression nor reversible by ectopic E2F1 
overexpression, indicating a stable transcriptional silencing in response to TERT 
deletion that cannot be attributed to a lack of E2F1 availability. Alternatively, a 
model in which E2F1 is present but unable to gain access to cognate binding sites 
due to condensed chromatin in TERT-deficient SMC appears conceivable. The 
ensuing altered transcription of E2F1-dependent genes in turn may provide a 
positive feedback to mechanisms that are upstream of Rb and induce its 
phosphorylation to overcome the proliferative arrest. Consistent with this concept 
is our observation that altered expression of E2F1 target genes in TERT-deficient 
SMC is associated with decreased E2F1 binding to their respective consensus 
motifs. To our knowledge these are the first data to demonstrate that E2F1-
dependent activation of S phase genes requires TERT expression. These findings 
complement the more widely appreciated function of telomerase in maintaining 
telomere repeats and provide a molecular mechanism underlying the well-
described, mitotic function of TERT.   
Using ChIP assays, we demonstrate that TERT is recruited along with E2F1 
to consensus sites within differentially regulated target genes. This inducible TERT 
occupancy of E2F1 sites is associated with the enrichment of CBP and permissive 
histone H3 acetylation on lysine 9 (K9Ac-H3). To confirm that TERT recruitment to 
E2F1 cognate elements is functionally important for the activation of chromatin, we 
probed for acetylated histone marks and chromatin accessibility. These studies 
revealed that TERT deletion decreases histone acetylation at E2F1 sites and 
reduces chromatin accessibility at the E2F1 site. Therefore, it is unlikely that the 
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mechanism by which TERT activates E2F1-target promoters is through direct DNA 
binding but rather involves chromatin remodeling and/or facilitated recruitment of 
other chromatin-modifying enzymes. CBP supports histone acetyltransferase 
activity required for E2F1 binding152. Our observations support that the association 
of TERT with CBP facilitates its recruitment to chromatin and local histone 
acetylation, which releases repressive chromatin. This hypothesis is further 
supported by the recent finding that TERT regulates Wnt-dependent transcription 
in stem cells through chromatin association and interaction with the chromatin 
modifier BRG160. BRG1 constitutes the energy-providing subunit of multiple 
chromatin-modifying enzymatic complexes to disrupt the chromatin architecture of 
target promoters and recruit histone acetyltransferases, which represent critical 
steps for E2F1-induced promoter activation152. Considering our observation that 
TERT depletion decreased chromatin accessibility and histone acetylation at E2F1 
sites, it is possible that TERT serves as a chaperone to facilitate the recruitment 
of BRG1 and/or histone acetyltransferase activity to E2F1 target sites. In addition 
to this mechanism, TERT has been reported to stabilize transcription factors 
through inhibition of ubiquitination153. However, since E2F1 protein levels were 
unaffected by TERT deletion we would consider this mechanism unlikely to explain 
the chromatin remodeling of TERT-deficient SMC.   
Based on our data, we conclude that transient re-expression of TERT during 
cell cycle progression provides a mechanism for the transcription of S phase cell 
cycle-regulatory genes. TERT is recruited to canonical E2F1 target genes and 
induces a permissive chromatin environment. In vivo, this mechanism is required 
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for the proliferative response of SMC to induce neointima formation. Further 
investigation of this novel epigenetic function of TERT and characterization of 
TERT-regulated gene expression programs will likely yield new insights into how 
TERT functions as a regulator of cell proliferation. 
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Figure 3.1 TERT is Expressed in Replicating Smooth Muscle Cells. 
A, Expression of TERT in SMC of human coronary artery atherosclerotic lesions. 
Sections of an early stage, SMC-rich fibroatheroma of a human coronary artery 
were immunostained for TERT and α-smooth muscle actin. Low resolution 
images (100X) and high resolution image (1000X) of the boxed area showing 
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TERT staining. B, Co-localization of TERT and PCNA in SMC of atherosclerotic 
lesions. TERT expression in proliferating SMC was detected by 
immunofluorescence staining of TERT (white), PCNA (red), and a-SMA (green) 
with nuclei counterstained with DAPI (blue) in sections of atherosclerotic 
coronary arteries compared with normal controls. Scale bar 100µM. C, Co-
expression of TERT and PCNA in the murine neointima following guide wire-
induced femoral artery injury. Tissues were stained for TERT (green), PCNA 
(red), and nuclei counterstained with DAPI (blue). Representative 
immunofluorescence staining of TERT and PCNA expression within injury-
induced neointima or sham arteries. Scale bar 50µM. 
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Figure 3.2 TERT is Required for Smooth Muscle Cell Proliferation. 
A, siRNA-induced TERT knockdown decreases SMC proliferation. Human 
coronary artery SMC were transfected with TERT siRNA and serum-deprived 
for 24 hours. Synchronized cells were then stimulated with FBS for 48 hours 
and counted using a hemocytometer. Cell numbers are presented as mean ± 
SEM relative to quiescent cells (#P<0.05 versus quiescent, *P<0.05 versus 
scrambled). B, Adenoviral-mediated overexpression of TERT promotes SMC 
proliferation. Serum-deprived human coronary artery SMC were transduced 
for 24 hours with 100 plaque-forming units (PFU) of adenoviral constructs 
overexpressing GFP/TERT (Adx-TERT/GFP) or GFP (Adx-GFP) as control. 
Following transduction, proliferation was analyzed after 48 hours by cell 
counting using a hematocytometer. Data are presented as mean ± SEM 
relative to quiescent GFP-infected cells (*P<0.05 versus Adx-GFP). C, 
Proliferation of vascular SMC isolated from TERT overexpressing 
(TERTtransgenic), littermate wildtype (TERTwildtype), first generation 
G1TERT-/-, littermate wildtype G1TERT+/+, and third generation G3TERT-/- 
mice (n=8 mice per group). Serum-deprived SMC were stimulated with FBS 
and counted at the indicated time points using a hemocytometer. Data are 
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presented as mean ± SEM (*P<0.05 versus the respective wildtype control 
mice). D, TERT overexpression rescues the mitogenic defect of TERT-
deficient SMC. Murine SMC from G1TERT-/- or G1TERT+/+ mice were 
infected with 100 PFU of Adx-TERT/GFP or Adx-GFP. Forty-eight hours after 
transduction, proliferation was analyzed by cell counting using a 
hematocytometer. Values are fold increase relative to G1TERT+/+ transduced 
by Adx-GFP and presented as mean ± SEM (#P<0.05 versus Adx-GFP, 
*P<0.05 versus G1TERT+/+).  
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Figure 3.3 TERT Deficiency Attenuates Neointima Formation. 
A, Photomicrographs of neointima formation in the femoral arteries of 
G1TERT+/+ and G1TERT-/- mice. Guide wire-induced endothelial denudation 
injuries were performed and tissues harvested after 28 days (n=8 per group). 
Tissues were stained using Verhoeff-van Gieson staining to visualize the 
internal and external elastic lamina. Scale bar represents 0.1 mm. B, The ratio 
of intima to media was calculated as the intimal area divided by the medial 
area. Data are presented as mean ± SEM (*P<0.05 versus G1TERT+/+). 
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Figure 3.4 TERT Deletion Induces Cell Cycle Arrest and is Required 
for E2F1 Target Gene Expression. 
A, TERT-deficiency decreases DNA synthesis. SMC from G1TERT+/+ or 
G1TERT-/- mice were serum-deprived and stimulated with FBS. After 24 
hours BrdU incorporation was quantified. Values are mean ± SEM (#P<0.05 
versus quiescent, *P<0.05 versus G1TERT+/+). B-C, TERT-deficiency 
induces cell cycle arrest. SMC were prepared as in A, and cell cycle 
distribution was analyzed by flow cytometry following propidium iodide 
staining. The percentages of cells in G0/G1, S, and G2/M phases (B) were 
calculated from flow cytometric plots of cell cycle distribution (C). Values are 
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mean ± SEM (#P<0.05 versus quiescent, *P<0.05 versus G1TERT+/+). 
Data were collected from three independently performed experiments (n=3 
per group). D-E, TERT deletion induces mitogen-induced 
hyperphophorylation of Rb. Cells were prepared as described in A. Whole 
cell lysate was blotted for phospho-Rb (Ser 807/811) and GAPDH as loading 
control. The autoradiograms shown (D) are representative of three 
independently performed experiments using different cell preparations. 
Densitometric quantification (E) normalized to GAPDH. Values are mean ± 
SEM (#P<0.05 versus quiescent, *P<0.05 versus G1TERT+/+) F, Silencing 
of S phase gene expression in G1TERT-/- SMC. SMC were stimulates with 
FBS as described above. mRNA expression of MCM7, cyclin A, and PCNA 
was analyzed by quantitative real-time PCR and normalized to transcript 
levels of the housekeeping gene TFIIB. Values are mean ± SEM (#P<0.05 
versus 0h, *P<0.05 versus G1TERT+/+ at the same time point). G-I, siRNA-
induced TERT deletion suppresses MCM7 expression in human coronary 
artery SMC. SMC were stimulated with FBS following transfection with 
TERT siRNA or scrambled control. MCM7 transcript and protein expression 
levels were analyzed by real-time PCR (G) and Western Blotting (H-I) after 
12 and 24 hours, respectively. Densitometric quantification (I) normalized to 
GAPDH. Values are mean ± SEM (#P<0.05 versus quiescent, *P<0.05 
versus Scrambled). 
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Figure 3.5 TERT is Recruited to Chromatin and Required for E2F1 
Binding to Target Promoters. 
A, Interaction of TERT and E2F1 in human coronary artery SMC. Cell 
extracts were immunoprecipitated (IP) with control IgG or anti-E2F1 
antibodies. Co-immunoprecipitated protein were visualized by Western 
Blotting (WB) using anti-TERT and anti-E2F1 antibodies. B, Mitogen-
induced recruitment of E2F1, TERT, and lysine 9-acetylated histone H3 
(K9Ac-H3) to target chromatin of the MCM7 promoter. Representative gel 
images of ChIP experiments performed in quiescent G1TERT+/+ SMC 
stimulated with FBS for 10 hours. Cells were harvested for ChIP using 
antibodies against E2F1, TERT, or K9Ac-H3 (indicated as IP). 
Immunoprecipitation with respective non-immune IgG served as control 
(indicated as IgG). Chromatin Input and non-template (NTC) are depicted 
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as additional controls. The precipitated chromatin was then amplified 
using primer pairs covering the E2F1 binding sites within the MCM7 
promoter. C, Mitogen-induced TERT recruitment to E2F1 target 
chromatin. Forty-eight hours after lentiviral transduction with either non-
targeting shRNA control (shCTL) particles or TERT shRNA (shTERT) 
particles, human coronary artery SMC were stimulated with FBS following 
24 hour serum-free starvation and then harvested for ChIP assays. 
Chromatin immunoprecipitation was performed using antibody against 
TERT. Promoter binding was quantified by real-time PCR using primers 
covering E2F1 binding sites within the MCM7 promoter. Cycle threshold 
(Ct) values were normalized to Ct values of input samples and presented 
as mean ± SEM (#P<0.05 versus quiescent, *P<0.05 versus shCTL). D-
F, TERT depletion abolishes mitogen-induced E2F1 binding to the 
promoters of MCM7 (D), cyclin A (E), and PCNA (F). Human coronary 
artery SMC were prepared as in described in (C). ChIP was performed 
using anti-E2F1 antibody. Quantification of immunoprecipitated chromatin 
by real-time PCR using primers covering E2F1 binding sites within the 
promoter regions of MCM7, cyclin A, and PCNA. Data are presented as 
mean ± SEM (#P<0.05 versus quiescent, *P<0.05 versus shCTL). 
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Figure 3.6. TERT-Deficiency Decreases Chromatin Accessibility 
and Histone Acetylation. 
A, Schematic illustration of locations of primers, Cac8I restriction sites, 
and E2F1 binding sites on MCM7 promoter. Sequences amplified by 
primers (arrows), Cac8I restriction sites (-312, -244, and -182 from the 
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transcription initiation site, triangles), and E2F1 binding sites (-297 and 
-250 from the transcription initiation site, squares) are noted. The 
transcription initiation site is marked as +1. B, TERT deletion decreases 
DNA accessibility of E2F1 binding sites within the MCM7 promoter. 
Nuclei isolated from FBS-stimulated SMC of G1TERT+/+ or G1TERT-/- 
mice were digested with Cac8I restriction enzyme and purified for 
ChART-PCR. Primers used for real-time PCR amplify sequences 
between nucleotides -346 and -176 in the MCM7 promoter, which 
encompass two E2F1 binding sites and three Cac8I restriction sites. 
Results were normalized against amplification of a control sequence 
upstream of the MCM7 promoter (nucleotides -620 to -513) with no 
Cac8I restriction sites. Data are presented as mean ± SEM relative to 
uncut samples (*P<0.05 versus G1TERT+/+). C, TERT depletion 
abolishes mitogen-induced histone H3 acetylation at the E2F1 
response elements within the MCM7 promoter. Human coronary artery 
SMC were treated as Figure 5C. ChIP was performed using an antibody 
against acetylated Histone H3 (Lys9). Quantification of 
immunoprecipitated chromatin was performed by real-time PCR using 
primers covering E2F1 binding sites within the promoters of MCM7. 
Data are presented as mean ± SEM (#P<0.05 versus quiescent, 
*P<0.05 versus shCTL). D-E, TERT-deficiency decreases acetylation of 
histone H3. Vascular SMC from G1TERT+/+ and G1TERT-/- mice were 
stimulated with FBS following 24 hour serum-free starvation and protein 
was harvested. Western Blotting was carried out using antibody against 
acetylated Histone H3 (Lys9). Histone H3 and GAPDH were used as 
loading contros. Densitometric quantification (E) normalized to H3. Data 
are presented as mean ± SEM (#P<0.05 versus quiescent, *P<0.05 
versus G1TERT+/+). F, Interaction of TERT and CBP in human coronary 
artery SMC. Immunoprecipitation (IP) of TERT from cell lysates followed 
by Western Blotting (WB) with anti-CBP. The same blot was 
subsequently stripped and re-probed with anti-TERT antibody. G, TERT 
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depletion reduces CBP recruitment to the E2F1 response element in 
the MCM7 promoter. Human coronary artery SMC were treated as in 
Figure 5C. ChIP was performed using anti-CBP antibody. Quantification 
of immunoprecipitated chromatin was performed by real-time PCR 
using primers covering E2F1 binding sites within the MCM7 promoter. 
Data are presented as mean ± SEM (#P<0.05 versus quiescent, 
*P<0.05 versus shCTL).  H-J, The proliferative defect induced by TERT-
deletion is not reversed by overexpression of E2F1. Vascular SMC from 
G1TERT+/+ and G1TERT-/- mice were transduced with 25 PFU/cell 
adenovirus overexpressing E2F1 or control GFP. MCM7 mRNA 
expression was analyzed by real-time RT-PCR after 24 hours (H). Cell 
proliferation was analyzed after 24 hours by cell counting using a 
hemocytometer (I) or by BrdU incorporation (J). Data are presented as 
mean ± SEM (#P<0.05 versus Adx-GFP, *P<0.05 versus G1TERT+/+). 
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4 CHAPTER FOUR 
Telomerase Reverse Transcriptase Deficiency  
Prevents Atherosclerosis Formation through an Inhibition of 
 Macrophage-Related Inflammation 
4.1 Abstract 
Objective: Telomerase Reverse Transcriptase (TERT), the catalytic subunit of 
telomerase, supports critical cellular processes required for tissue remodeling. 
Previous studies established that TERT expression is induced in activated 
macrophages and during experimental and human atherosclerosis formation. In 
the present study, we investigated the role of TERT in atherosclerosis 
development and macrophage inflammation.   
Approach and Results: TERT-deficient mice were crossbred with LDL-receptor-
deficient (LDLr-/-) mice to generate first generation G1TERT-/-LDLr-/- offsprings, 
which were then successively intercrossed to obtain the third generation G3TERT-
/-LDLr-/- mice. G1TERT-/-LDLr-/- mice displayed no telomere shortening while 
severe telomere attrition was evident in G3TERT-/-LDLr-/- mice. When fed on an 
atherogenic diet, G1TERT-/-LDLr-/- and G3TERT-/-LDLr-/- mice were both 
protected from atherosclerosis formation compared to their wildtype controls, 
indicating that genetic TERT-deletion prevents atherosclerosis, and formation of 
the disease is not affected by telomere attrition. Similarly, atherosclerosis 
development was decreased in chimeric LDLr-/- mice with TERT deletion in 
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hematopoietic stem cells after bone marrow transplantation. TERT deficiency 
reduced macrophage accumulation in atherosclerotic lesions and altered 
chemokine expression, including CXC1/2/3, CCL3, CCL5, CCL21, CCR7, IL-6, 
and IL-1α.  In isolated macrophages, sequence analysis of silenced inflammatory 
gene promoters indicated that TERT deletion altered signal transducer and 
activator of transcription 3 (STAT3)-dependent chemokine expression and 
recruitment of phosphorylated STAT3 to its target promoters. Mechanistically, 
TERT expression was necessary and sufficient to maintain STAT3 
phosphorylation.  
Conclusions: Our data support that genetic TERT deficiency decreases 
atherosclerosis formation by silencing inflammatory chemokine transcription 
through inactivation of the STAT3 signaling pathway.  
4.2 Introduction 
Telomeres are repetitive DNA-protein complexes that protect the ends of 
chromosomes and are maintained by the enzyme telomerase44. TERT confers the 
catalytic activity and is the limiting factor for telomerase activation26, 110. 
Overexpression of TERT in cancer and stem cells confers a virtually unlimited 
replicative capacity61, 128, 154. In contrast, most somatic cells are thought to 
suppress telomerase activity by silencing the TERT gene, resulting in telomere 
shortening and limited replicative potential44. While this traditional role of TERT in 
maintaining telomeres is firmly established, mounting evidence points to a second 
role of TERT in the control of cell signaling and gene expression that is 
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independent of its reverse transcriptase activity and ability to elongate telomeres47. 
For example, overexpression of TERT has been demonstrated to activate gene 
transcription by chromatin modulation60. Also, multiple studies have revealed that 
TERT activates various signaling pathways, including MAP-kinase89 and NF-kB 
signaling58, through a telomere maintenance-independent mechanism.  
Leukocyte telomere length shortens with age in humans, and telomere 
dysfunction has been linked to a host of pathologies including dementia, 
cardiovascular events, asthma, diabetes, and stroke43, 67. Therefore there has 
been an increasing interest in the reactivation of telomerase, the enzyme to 
elongate telomeres, to protect against cellular senescence and age-related 
diseases62. However, in contrast to the circulating leukocyte telomere shortening 
that is generally associated with cardiovascular risk155, long telomere length69 and 
telomerase activation70, 71 are observed in leukocytes isolated directly from human 
unstable coronary artery plaques. Furthermore, atherosclerosis is decreased in 
apoE-deficient mice with short telomeres due to lack of the telomerase component 
that provides the RNA template to the enzyme84. Collectively, these results 
challenge the general dogma that telomerase activation may prevent vascular cell 
dysfunction and atherosclerosis development.   
Considering this important function of telomerase in cell biology, 
surprisingly little is known about the function of telomerase and telomere-related 
molecular processes in atherosclerosis. TERT expression is thought to be 
essential in preventing EC senescence72, 73. Our laboratory has further 
demonstrated that TERT is inducible in proliferating vascular smooth muscle cells 
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(VSMC) and represents a mitogenic effect30, 31. Furthermore, our recent studies 
confirmed an increased TERT expression in macrophages of human 
atherosclerotic lesions71, indicating a potentially important function of TERT in 
vascular remodeling.  However, the role of TERT in atherosclerosis has not been 
investigated. 
4.3 Materials and Methods 
Immunohistochemical Staining 
For immunohistochemical staining of TERT expression in human coronary 
atherosclerotic lesions, segments of coronary arteries were harvested from 
explanted hearts during cardiac transplantation as described. Tissues were fixed 
in 4% phosphate-buffered formaldehyde and embedded in paraffin, and transverse 
sections (8 µm) were collected. Serial paraffin-embedded sections were incubated 
with a rabbit monoclonal TERT antibody (600-401-252S, Rockland) or mouse 
monoclonal CD68 antibody (ab955, Abcam), followed by biotinylated goat anti-
rabbit IgG (BA-1000, Vector Laboratories) or biotinylated goat anti-mouse IgG (BA-
9200, Vector Laboratories) and counterstaining with hematoxylin. For 
immunofluorescent colocalization studies, tissues were incubated with antibodies 
raised against TERT (600-401-252S, Rockland) or p-STAT3 (9145S, Cell 
Signaling), and CD68 (ab955, Abcam), followed by incubation with Alexa Fluor 
488-conjugated goat anti-mouse, and Alexa Fluor 594-conjugated goat anti-rabbit
antibodies (A11001 & A11012, Invitrogen) and counterstaining with DAPI. 
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Mice 
Littermate TERT+/+ and TERT-/- mice on a mixed C57BL/6J background 
were used (The Jackson Laboratory, Stock Number 005423). First generation 
G1TERT-/- mice derived from heterozygote founder mice were further mated to 
generate late generation, i.e. third generation G3TERT-/- mice. G1TERT-/- and 
G3TERT-/- with their respective littermate were crossbred with male low-density 
lipoprotein receptor–deficient mice (LDLr-/-, The Jackson Laboratory) to generate 
G1 and G3TERT-/-LDLr-/- mice. Study mice and their littermate controls were fed 
a saturated fat-enriched diet for 12 weeks to induce atherosclerosis formation 
(Harlan Teklad TD.88137). 
Bone marrow transplantation (BMT) was performed by repopulating lethally 
irradiated male LDLr-/- mice (The Jackson Laboratory) with bone marrow–derived 
cells of male first-generation TERT-deficient mice (TERT-/-, The Jackson 
Laboratory, B6.129S-Terttm1Yjc/J, stock number 005423) or their wild-type 
littermates (TERT+/+). Briefly, mice were maintained on water containing 
antibiotics (sulfamethoxazole/trimethoprim) for one week before BMT until four 
weeks after BMT. Recipient mice were irradiated with a total of 900 Rads from a 
cesium source that was delivered in 2 doses within 3 to 4 hours. Bone marrow–
derived cells of male TERT+/+ or TERT-/- mice were obtained from the tibias and 
femurs of donor mice and were injected into the tail vein of 8-week-old irradiated 
male LDLr-/- recipient mice (1.2×107 cells per mouse, n=10 with TERT+/+ and n=7 
with TERT-/-). After four weeks of recovery, a saturated fat-enriched diet was fed 
for 12 weeks until the end of the study (Harlan Teklad TD.88137). All studies were 
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performed with the approval of the University of Kentucky Institutional Animal Care 
and Use Committee. 
Atherosclerosis Quantification 
En face atherosclerosis was quantified as lesion area on the intimal surface 
of aortic arches. The entire aorta from the aortic root to the common iliac arteries 
was removed from the sacrificed mice. The intimal surface is exposed by a 
longitudinal cut through the inner curvature of the aortic arch and down the anterior 
aspect of the remaining aorta. The tissue is then pinned to a dark surface, and the 
lesions are observed through a dissecting microscope. The area of atherosclerotic 
lesions was quantified and represented as percent of the total intimal surface. 
Quantification of Macrophage and Foam Cell Accumulation 
Aortic roots were frozen in OCT media (Tissue-Tek, Sakura Finetek, 
Torrance, CA) and serial 10 µm sections were cut as previously described103. 
Accumulation of lipids in lesions was visualized by staining with Oil Red O. 
Macrophages were detected by immunohistochemistry staining using anti-CD68 
antibody (ab955, Abcam). Percentage of macrophage and lipid (Oil Red O 
positive) area in aortic root plaques was calculated using computer-assisted image 
analysis (Image-Pro, Media Cybernetics, Rockville, MD).  
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Telomere Length Quantification 
For quantification of telomere length using real-time PCR, DNA was isolated 
from bone marrow differentiated macrophages (BMDM) of G1TERT+/+, G1TERT-
/-, G3TERT-/-, was isolated harvested from TERT-/- samples were run in triplicate 
with 35 ng of DNA per reaction using an iCycler and SYBR Green I system (Bio-
Rad) as described. Telomere repeat copy number data were normalized to 36B4 
as the single-copy gene. Below lists the primer sequences. 
tel 1: 5'-GTTTTTGAGGGTGAGGGTGAGGGTGAGGGTGAGGGT-3';  
tel 2: 5'-TCCCGACTATCCCTATCCCTATCCCTATCCCTATCCCTA-3'; 
36B4 forward: 5'-CAACCCAGCTCTGGAGAAAC-3';  
36B4 reverse: 5'-AAGCCTGGAAGAAGGAGGTC-3'.  
Quantitative fluorescence in situ hybridization on metaphase chromosomes 
was performed using Cy-3 labeled (CCCTAA) PNA probe (Telomere PNA Fish 
Kit/Cy3, Dako, K5326) to analyze the telomeric sequences in BMDM. Cells were 
counterstained with DAPI to visualize the chromosomes.  
Quantification of Total Cholesterol Concentration and Lipoprotein-
Cholesterol Distribution 
Total plasma cholesterol concentration and lipoprotein-cholesterol 
distribution were analyzed as previously described. Briefly, total plasma 
cholesterol was measured by an enzymatic colorimetric method using the Wako 
Cholesterol E kit (Wako Chemicals, Richmond, VA). Lipoprotein-cholesterol 
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distribution was detected by size exclusion chromatography using a fast 
performance liquid chromatographic machine (Pharmacia GE Healthcare Life 
Sciences, Pittsburgh, PA). 
Cell Culture 
Mouse BMDM were isolated from the femurs of mice and differentiated 
using Dulbecco's modified Eagle's medium (DMEM, Invitrogen) supplemented with 
20% fetal bovine serum and 30% L929 cell-conditioned medium for ten days. 
BMDM isolated from G1TERT-/- mice or wild-type littermates (n = 6/group) were 
treated with 100 ng/ml lipopolysaccharide (LPS) for the indicated time before RNA 
or whole cell lysate collection.  
NanoString Gene Expression Analysis 
Inflammatory gene expression was profiled using nCounter GX mouse 
inflammation kit consisting of 184 inflammation-related genes and six internal 
reference genes.  Briefly, RNA was collected from cells with Trizol (Invitrogen, 
Grand Island, NY). 10ng of purified RNA was hybridized against the nCounter GX 
mouse inflammation kit (NanoString Technologies, Seattle, WA) and data were 
analyzed using nSolver Analysis Software (NanoString Technologies, Seattle, 
WA). The geometric mean of the code counts for the positive control genes was 
used for normalization. 
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Gene Ontology Enrichment Analysis 
LPS-induced inflammatory genes changed more than 1.5 fold by TERT 
deletion are included in Gene Ontology (GO) biological process enrichment 
analysis. Enrichment analysis was performed using the Gene Ontology 
Consortium (Http: //geneontology.org/page/go-enrichment-analysis) based on 
biological process terms.  
Western Blotting 
Western blotting was performed as described using antibodies against p-
STAT3 (Tyr705) (9131, cell signaling), total STAT3 (12640, cell signaling), and 
GAPDH (FL 335, Santa Cruz). 
Flow Cytometry 
For phenotypic identification of hematopoietic stem cells (HSC), progenitor 
cells, and mature hematopoietic cells, cells were stained with cell surface markers 
and analyzed by flow cytometry. Bone marrow cells were stained with the 
differentiated lineage cell markers (CD5, CD3, B220, Mac-1, Gr-1, and Ter119 
from BD Pharmingen, San Jose, CA) and stem cell markers (Sca-1 from 
Invitrogen, Grand Island, NY, c-kit from BD Pharmingen, San Jose, CA). The HSC-
enriched population is negative for the lineage markers but positive for Sca-1 and 
c-kit (Lin-Sca-1+c-kit+). Committed progenitor cells, macrophage and dendritic
progenitors (MDP) were identified by the markers of CD16/CD32 (eBioscience, 
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San Diego, CA), and CD115 (BD Pharmingen, San Jose, CA) and were identified 
as Lin-Sca-1- c-kit+ CD16/CD32+CD115+. Dead cells were excluded by propidium 
iodide selection. Bone marrow cells were analyzed and sorted on a BD FacsAria 
II flow cytometer (Becton Dickinson, San Jose, CA). Each experimental group was 
sorted independently. Flow cytometry and fluorescence-activated cell sorting 
(FACS) data were analyzed using FlowJo software (Tree Star, Ashland, OR)  
For identification of mature hematopoietic cells in blood, granulocytes were 
identified as CD3e-CD19-NK1.1-CD11b+Ly6Ghi; total monocytes were identified 
as CD3e-CD19-NK1.1-Ly6G-CD11b+CD115+, and monocyte subsets were 
identified as Ly6C+ monocytes or Ly6C- monocytes by Ly6C fluorescence 
intensity gated on total monocytes. Antibodies used for staining are as follows: 
APC-Cy7 mouse CD11c, FITC mouse Ly6C, PE-cy7 mouse Ly6G, Percp-cy5.5 
mouse CD11b (BD Biosciences, San Jose, CA); PE anti-mouse CD115 
(Biolegend, San Diego, CA). Antibodies were used according to the manufacturer's 
protocol. Cellular fluorescence was assessed with FACSCalibur (BD Biosciences, 
San Jose, CA) and data were analyzed with Cell Quest software (version3.3, 
Becton Dickinson, San Jose, CA). 
Transfection of HEK 293 Cells 
HEK 293 cells were transiently transfected with a TERT or green fluorescent 
protein expression vector using Lipofectamine 2000 (Invitrogen, Grand Island, NY) 
as described. 24 hours after transfection, cells were treated with LPS (1ug/ml) or 
IL-6 (10ng/ml) for 30 minutes before whole cell lysates were collected.  
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Statistical Analysis 
Results were represented as means or medians depending on the 
distribution of data. Unpaired Student's t-test was used to compare the means 
between two independent groups on a single variable. The effect of TERT on 
atherosclerosis was compared using the Kruskal-Wallis test followed by Dunn Test 
post hoc analysis. P values <0.05 were considered to be statistically significant. 
4.4 Results 
4.4.1 TERT Is Expressed in Macrophages from Atherosclerotic Lesions in 
Human Coronary Artery 
To confirm that TERT is expressed in complex atherosclerotic lesions in 
vivo, we performed immunohistochemical analysis on human coronary arteries. 
Consistent with our earlier report, we found significant TERT expression within the 
atherosclerotic lesions of human coronary arteries whereas in healthy arteries its 
presence is negligible. Unusually high levels of TERT expression were observed 
in the macrophage-rich shoulder region of advanced atherosclerotic lesions. As 
shown by immunofluorescent staining, TERT colocalized with macrophage CD68 
in the atherosclerotic lesions (Figure 4.1. A-B). These observations confirm a 
pathological overexpression of TERT by macrophages in human atherosclerotic 
lesions. 
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4.4.2 Telomere Length Is Preserved in Early Generation of TERT-Deficient 
Mice 
TERT-/- mice (The Jackson Laboratory, Stock Number 005423) were used 
to test whether TERT deletion affects atherosclerosis formation. First generation 
G1TERT-/- mice derived from heterozygote founder mice exhibited normal 
telomere lengths and no phenotypes associated with telomere attrition. However, 
intercrossing of G1TERT-/- mice results in progressive telomere loss in 
subsequent generations. Therefore, this unique system is useful in two aspects: it 
allowed the investigation of telomere-independent functions of TERT in G1TERT-
/- mice, as well as the phenotypes that occur as a result of telomere attrition in the 
third generation G3TERT-/- mice. The described alterations of telomere attrition 
are documented in Figure 4.2. A-C. 
4.4.3 Early and Late Generations of TERT-Deficient Mice Show 
Comparable Reduction in Atherosclerosis Formation 
While TERT expression is upregulated in the atherosclerotic lesions, it is 
not known whether TERT expression contributes to atherosclerosis development. 
To address this question, we generated an atherosclerosis mouse model by 
crossbreeding G1TERT-/- or G3TERT-/- mice with LDLr-/- and fed a high-
cholesterol diet. G1TERT-/-LDLr-/- mice developed fewer atherosclerotic lesions 
compared to littermate G1TERT+/+LDLr-/- mice, but no difference was found 
between G1 and G3TERT-/- LDLr-/- mice (Figure 4.3. A-E), indicating that TERT 
deletion in the presence of normal telomere length decreases atherosclerosis 
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through a mechanism that is not associated with telomere shortening. TERT 
deletion did not affect plasma cholesterol concentration and lipoprotein distribution 
(Figure 4.4. A-B), indicating an intrinsic role of TERT to promote atherosclerosis 
formation. 
4.4.4 TERT Deficiency in Bone Marrow Prevents Atherosclerosis 
Formation and Macrophage Recruitment in LDLr-/- Mice 
 Given that the expression of TERT by infiltrating macrophages in 
atherosclerotic plaques was significantly higher compared to that of normal control 
arteries, and whole body TERT deletion ameliorated atherosclerotic formation, we 
hypothesize that the aberrant TERT expression in macrophages is key to the 
development of atherosclerosis through enhanced vascular inflammation. Bone 
marrow of TERT-null donors was transplanted to LDLr-/- mice which resulted in 
the depletion of TERT in the hematopoietic lineage. As depicted in Figure 4.5.A-
D, macrophage infiltration and aortic lipid content were decreased in these 
chimeric mice after 12 weeks of the atherogenic diet, indicating that the selective 
deletion of TERT in bone marrow prevented atherosclerosis formation by 
decreasing macrophage recruitment into the arterial wall. 
As monocytosis resulted from hypercholesterolemia-induce hematopoiesis 
contributes to atherosclerosis, we next quantified bone marrow resident HSC and 
MDP populations as well as the leukocyte and monocyte subsets sampled from 
systemic circulation. Bone marrow deletion of TERT did not change the counts of 
all the cell sets examined (Figure 4.6. A-D). Therefore, the proliferation of HSC and 
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MDP, as well as the corresponding monocyte differentiation, are not the potential 
mechanisms for TERT-induced atherosclerosis formation.    
4.4.5 Inflammatory Genes Are Silenced in G1TERT-/- Macrophages 
The observations that TERT deletion reduces atherosclerosis formation in 
mice with normal telomeres and monocyte counts, led us to hypothesize that TERT 
induces atherosclerosis through mechanisms other than the well-established 
functions of TERT in telomere maintenance. Since TERT has recently emerged as 
a transcriptional regulator to modulate the expression of genes independently of 
its telomerase activity, we employed the NanoString technique to analyze 
transcript levels of 184 inflammatory genes in BMDM induced by LPS treatment. 
As shown in Figure 4.7. A-C, multiple genes associated with atherosclerosis 
formation were found to be expressed at significantly lower levels in G1TERT-/- 
BMDM. These include a host of inflammatory cytokines known to be involved in 
atherosclerosis formation, including IL-6, TNFα, IL-1α and IL-1β, and various 
members of the CC/CXC chemokine family. These findings indicate that TERT 
may be required for the expression of inflammatory genes in macrophages without 
affecting telomere homeostasis.  
4.4.6 TERT Activates STAT3 Signaling 
As shown in Figure 4.8. GO enrichment analysis of TERT-regulated target 
genes using the “biological processes” terms revealed that significantly enriched 
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processes (P ≤ 0.01) include chemotaxis, cellular response to IL-1 or IFNɣ, and 
STAT cascade activation. These hypothesis-generating data indicate that tyrosine 
phosphorylation of STAT protein may constitute an underlying mechanism of 
TERT-regulated chemokine and cytokine secretion in macrophages. To address 
this question, we next investigated whether TERT-deletion in G1TERT-/- BMDM 
affected STAT3 phosphorylation as the underlying transcriptional mechanism of 
TERT-regulated chemokine and cytokine expression. As depicted in Figure 4.9. A-
D, LPS-induced STAT3 phosphorylation was reduced in G1TERT-/- BMDM. Using 
a transgenic mouse model of TERT overexpression (TERT-Tg, kindly provided by 
Dr. Chiang) we confirmed that TERT overexpression in BMDM activated STAT3 
phosphorylation. In addition, STAT3 activation by TERT was also observed in 
human 293 cells stimulated with either LPS or IL-6. Furthermore, we identified 
decreased p-STAT3 levels in atherosclerotic plaque-associated macrophages in 
LDLr-/- mice with a bone marrow deletion of TERT (Figure 4.10. A-B).   
4.5 Discussion 
 Macrophages are a critical source of the chronic inflammation and vascular 
remodeling processes that are key to the initiation and development of 
atherosclerosis formation156. Among the mechanisms that orchestrate tissue 
remodeling and repair, telomerase activation is thought to control essential cellular 
functions including cell activation, replicative lifespan, differentiation, and 
proliferation157. An upregulated expression of TERT, the catalytic subunit of 
telomerase, was observed in activated macrophages during atherosclerosis 
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formation71. However, the mechanism that underlies this regulation and functional 
consequences remains unknown. In the current study, we demonstrate that 
genetic TERT depletion prevents atherosclerosis formation in both early and late 
generation TERT-deficient mice. Based on these observation, we infer that TERT-
deficiency protects from atherosclerosis through mechanisms other than telomere 
attrition. Similarly, atherosclerosis development was decreased in chimeric LDLr-
/- mice with TERT deletion in hematopoietic stem cells following bone marrow 
transplantation. In isolated macrophages, TERT deficiency reduced the 
expression of multiple chemokines, which are well known to be causally involved 
in the formation of atherosclerosis. All regulated target genes are STAT3-induced 
genes, consistent with results obtained from our GO enrichment analysis. 
Furthermore, we documented a decrease of STAT3 phosphorylation in TERT-
deficient BMDM while TERT overexpression enhanced STAT3 phosphorylation in 
mouse BMDM and in human 293 cells. Finally, decreased STAT3 activation was 
confirmed in vivo by a decrease of STAT3 phosphorylation in macrophages of 
atherosclerotic plaques isolated from LDLr-/- mice with TERT-depleted bone 
marrow. These findings suggest that genetic TERT deficiency reduces 
atherosclerosis formation by silencing inflammatory chemokine transcription 
through altered STAT3-dependent signaling.  
Telomere length shortening with successive cell divisions has been 
proposed to serve as biomarker of biological aging67. Therefore, there has been a 
growing interest in utilizing telomere extension as a preventive strategy against 
age-related diseases, including atherosclerosis62.  However, previous studies have 
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identified that telomere length and telomerase activity are increased in human 
atherosclerosis, particularly in leukocytes isolated directly from unstable coronary 
artery plaques69, 70. Consistent with this finding, we observed increased TERT 
expression in macrophages isolated from human atherosclerotic lesions71. 
Importantly, TERT deficiency in this macrophage population was shown to protect 
mice against atherosclerosis. Furthermore, atherosclerosis was decreased to a 
similar extent in LDLr-/- mice crossbred with either early generation or late 
generation of TERT-/- mice. These data indicate that the mechanism of 
atherosclerosis prevention associated with genetic TERT deletion is dependent on 
TERT deletion but independent of telomere length maintenance because telomere 
length in the early generation of TERT-/- mice was indistinguishable from the wild-
type littermates. In addition to our findings, numerous studies have identified 
telomere-independent functions of TERT involved in essential biological 
processes, including cellular proliferation, differentiation, apoptosis, and DNA 
repair response48. Therefore, it is possible that TERT functions through an 
alternative mechanism to regulate the viability and function of cells within the 
arterial wall, ultimately affecting the outcome of atherosclerotic development. 
However, the similar degree of atherosclerosis prevention in G1 and G3 TERT-
deficient mice cannot be interpreted by telomere length variation during the 
process of atherosclerosis formation. Increased telomere uncapping following 
telomere erosion could provoke important consequences, including chromosomal 
end-to-end fusions, aneuploidy, and impaired stress responses158. Moreover, to 
date, there is no evidence from human studies showing that telomere attrition in 
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leukocytes causes atherosclerosis. In contrast to the general notion that short 
telomere length constitutes a hallmark of cardiovascular events68, there was a 
decrease in atherosclerosis in mice with short telomeres due to the proliferative 
limitation of immune cells84. Therefore, the role of telomere shortening in 
atherosclerosis is inconclusive. Our current result indicate that TERT deletion 
attenuates atherosclerosis formation through a mechanism that is likely unrelated 
to telomere length regulation.  
TERT expression in vascular cells, including VSMC and endothelial cells 
(EC), is critical for cellular functions and adaptations during vascular remodeling 
and may exert anti-atherosclerotic effects through the protection against cellular 
senescence30, 31, 72, 73. Therefore, the absence of TERT in these resident cells in 
our whole-body TERT deletion experiments may confound our mechanistic 
interpretation on the pro-inflammatory role of TERT specifically in macrophages. 
Consequently, chimeric LDLr-/- mice with hematopoietic deletion of TERT using 
bone marrow transplantation enabled us to extend these observations and 
determine whether TERT-dependent activation of macrophages contributes to 
atherosclerosis formation159. Similarly, bone marrow deletion of TERT suppresses 
atherosclerosis development and macrophage accumulation within the 
atherosclerotic lesion, implying a macrophage-specific effect of TERT to promote 
atherosclerosis formation. TERT expression in macrophages is induced during the 
activation of immune cells. Multiple studies have revealed that TERT activates 
various inflammatory signaling pathways, including MAP-kinase89 and NF-kB 
signaling58, and effect that is mediated through telomere maintenance-
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independent mechanisms. In line with these findings, our current study shows that 
TERT deletion reduces the expression of multiple inflammatory cytokines and 
prevents STAT3 activation. STAT3 signaling pathway is activated by a broad range 
of growth factors and cytokines160. Following phosphorylation, activated STAT3 
transiently translocates from the cytoplasm to the nucleus, where it functions as a 
core transcription factor regulating the expression of a large number of genes 
associated with proliferation, survival, and inflammation161. During innate 
immunity, STAT3 serves as an essential downstream target of Toll-like receptor 4 
(TLR4)162 and IFNɣ pathways163 and is involved in the extensive network of the 
inflammatory signaling pathways, including MAP-kinase16, NF-κB164, and PI3K 
signaling165. Therefore, STAT3 is increasingly recognized as a central signaling 
molecule to control cellular adaption in response to environmental stimuli or stress 
responses in EC, VSMC, and inflammatory cells166. In macrophages, STAT3 
activation polarizes macrophages from the pro-inflammatory M1 to the anti-
inflammatory M2 type and exacerbates or reduces inflammation in a context-
dependent manner24, 167, 168. Given the multiple functions of STAT3 in various 
biological processes and the complex interactive network between STAT3 and 
other inflammatory signaling pathways, our study demonstrates a novel permissive 
effect of TERT on pro-inflammatory macrophages through the activation of STAT3. 
Telomerase activity is upregulated in response to cytokine-induced 
proliferation and cell cycle activation in human hematopoietic cells169. Moreover, 
ectopic overexpression of TERT is directly associated with the proliferative 
capacity of stem cells and may exert an additional role in lineage differentiation170, 
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171. Therefore, we examined the proliferation and differentiation of HSC, progenitor 
cells, peripheral leukocytes and monocytes in LDLr-/- mice reconstituted with 
TERT-/- bone marrow. As expected, bone marrow deletion of TERT did not affect 
the numbers or composition of these cell lineages. Previously it has been 
demonstrated that critical telomere shortening reduces the response to 
hematopoietic ablation158 and HSC engraftment172. However, in our studies 
telomere shortening was not evident in leukocytes isolated from first generation 
TERT-deficient mice173. The dissociation of telomerase activity and telomere 
maintenance in human HSC was also noted by Wang et al.174. Furthermore, 
multiple studies have identified that the prolonged self-renewal of HSC is not 
limited by TERT deletion173, 175. All these findings indicate that stem cells from 
early-generation TERT−/− mice with normal telomere lengths can provide efficient 
hematopoietic recovery with an adequate amount of functional daughter cells. 
Therefore, TERT contribution to atherosclerosis formation is unlikely a result of 
alterations in leukocytosis or monocytosis, a well-established mechanism for 
atherosclerosis formation7, 176-178.   
In summary, the current study demonstrates a TERT-dependent activation 
of the STAT3 signaling pathway and pro-inflammatory macrophage phenotype, 
which consequently contributes to atherosclerosis formation. Our findings provide 
novel insights into the mechanisms controlling inflammatory gene expression and 
characterize TERT as a previously unrecognized regulator of atherosclerosis.  
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Figure 4.1 TERT is Expressed in Macrophages of Human Coronary Artery 
Atherosclerotic Lesions. 
A. Representative IHC and IF images of serial sections of human coronary 
arteries from healthy or atherosclerosis patient. Segments of healthy (Left) and 
atherosclerotic (Right) human coronary arteries were harvested during an 
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autopsy. For immunohistochemistry staining (IHC), paraffin-embedded sections 
were stained for TERT, followed by hematoxylin counterstaining. TERT positive 
staining is red. Note the lack of TERT staining in normal coronary arteries 
compared with the abundant immunoreactivity against TERT in the shoulder 
region of atherosclerotic lesions. The serial sections of those used for IHC were 
applied for immunofluorescence staining (IF) to detect TERT and macrophage 
co-localization in the atherosclerotic lesion. Sections were stained for 
macrophage marker CD68 (green), TERT (red), and counterstained with 4′,6-
diamidino-2-phenylindole (DAPI) to visualize nuclei (blue, lower left panel). The 
merged images show the composite staining. The co-localization of CD68 and 
TERT immunoreactivity is yellow. Scale bar, 100µm. B. Quantification of TERT-
positive macrophages within human coronary artery atherosclerotic lesion. 
Paraffin-embedded sections of healthy (n=5) and atherosclerotic (n=3) human 
coronary arteries were stained for TERT and macrophage marker CD68 by IF 
as described in A. The number of TERT-positive macrophages within the 
atherosclerotic lesions was counted from four equally distributed sites on each 
coronary artery segment using software ImageJ. Results are presented as mean 
± SEM (*P<0.05 vs. normal control). 
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Figure 4.2 Telomere Lengths are Preserved in G1TERT-/- mice but 
Significantly Decreased in G3TERT-/- Mice. 
A-B. Quantification of telomere lengths by real-time PCR in bone marrow 
differentiated macrophages from (A) TERT+/+, G1TERT-/- and G3TERT-/- mice 
(n=3 per group) and (B) TERT+/+LDLr-/-, G1TERT-/-LDLr-/- and G3TERT-/-LDLr-/- 
mice (n=5 per group). The copy number of telomere repeats was normalized to 
that of a single-copy gene (36B4). Values are mean ± SEM (* p<0.05 vs. 
TERT+/+). C. Representative telomeric fluorescence in situ hybridization assay 
on metaphase chromosomes of TERT+/+, G1TERT-/- and G3TERT-/- bone 
marrow differentiated macrophages. DAPI-stained chromosomes and Cy-3–
labeled telomeres are shown in blue and red, respectively.   
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Figure 4.3 Early and Late Generation of TERT-Deficient Mice Present 
Comparable Reduction in Atherosclerosis Formation. 
A. TERT-/-LDLr-/- mice developed fewer atherosclerotic lesions compared with 
TERT+/+LDLr-/- mice but no difference was found between G1TERT-/-LDLr-/- 
and G3TERT-/-LDLr-/-. Thoracic atherosclerotic lesion size was measured by 
en face analysis. The effect of TERT on atherosclerosis was compared using 
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the Kruskal-Wallis test followed by Dunn Test post-hoc analysis. Circles and 
triangles represent individual mice; diamonds represent medians (* p<0.05 vs. 
G1TERT+/+LDLr-/-). B. Quantification of lipid content from oil red O staining. 
Circles represent individual mice; diamonds represent medians (* p<0.05 vs. 
G1TERT+/+LDLr-/-). C. Representative Oil Red O staining of aortic root 
sections. Neutral lipids are stained red. Scale bar, 200µM. D. Quantification of 
macrophage content from macrophage immunostaining. Circles represent 
individual mice; diamonds represent medians (* p<0.05 vs. G1TERT+/+LDLr-/-). 
E. Representative immunostaining of aortic root sections using rabbit anti-
mouse CD68 antibody to label macrophages. Positive cells are stained red. 
Scale bar, 200µM.  
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Figure 4.4 TERT Deletion does not Affect Plasma Cholesterol 
Concentration and Lipoprotein Distribution. 
A. Total plasma cholesterol (TC) concentration measured by an enzymatic 
colorimetric method. Values are mean ± SEM. B. Lipoprotein cholesterol 
distribution analyzed by size exclusion chromatography. Values represent each 
fraction by mean ± SEM.  
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Figure 4.5 Early and late generation of TERT-deficient mice present 
comparable reduction in atherosclerosis formation. 
Bone marrow transplantation (BMT) was applied to conditionally delete TERT 
expression in the hematopoietic system. LDLr-/- mice reconstituted with wildtype 
or TERT-deficient bone marrow were fed on an atherogenic diet for 12 weeks, 
then atherosclerosis was analyzed by quantification of lipid and macrophage 
content in the aortic roots. A. Quantification of lipid content from Oil Red O 
staining. Circles represent individual mice; diamonds represent medians (* 
p<0.05 vs. BMT G1TERT+/+LDLr-/-). B. Representative Oil Red O staining of 
aortic root sections. Neutral lipids are stained red. Scale bar, 200µM. C. 
Quantification of macrophage content from macrophage immunostaining. 
Circles represent individual mice; diamonds represent medians (* p<0.05 vs. 
BMT G1TERT+/+LDLr-/-). D. Representative immunostaining of aortic root 
sections using rabbit anti-mouse CD68 antibody to label macrophages. Positive 
cells are stained red. Scale bar, 200µM.  
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Figure 4.6 Bone Marrow Deletion of TERT Does not Alter the Counts of 
HSC, MDP, and Blood Cells. 
A. Quantification of hematopoietic stem cells (HSC) and macrophage and dendritic 
progenitors (MDP) in bone marrow of chimeric LDLr-/- mice received TERT+/+ or 
TERT-/- bone marrow (n=10 per group) using flow cytometry. Values are mean ± 
SEM B. Quantification of differential white blood cell populations in LDLr-/- mice 
reconstituted with TERT+/+ or TERT-/- bone marrow (n=10 per group) analyzed 
by flow cytometry. T, T cells; B, B cells; Gran, granulocytes; Mono, monocytes; 
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NK, natural killer T cells; DC, dendritic cells. Values are mean ± SEM. C. 
Quantification of monocyte subsets in the blood of LDLr-/- mice reconstituted with 
TERT+/+ or TERT-/- bone marrow (n=10 per group) by flow cytometry. Values are 
mean ± SEM. D. Gating strategy for identification of HSC, MDP, and leukocytes 
by flow cytometry.   
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Figure 4.7 TERT-Deficient Macrophages Display Silenced Inflammatory 
Gene Expression. 
A. G1TERT-/- or G1TERT+/+ BMDM were treated with 100ng/ml LPS for 8 
hours. Inflammatory gene expression was analyzed by the NanoString nCounter 
Analysis System. A. Heat map of LPS-induced genes changed more than two-
fold with TERT deletion. Each colored square on the heat map represents the 
relative transcript abundance (in log2 space) of each gene with the high 
expression being red and the low expression being green. Each column 
represents one group (n=3 per group) and each row shows the transcript level 
of one gene. B-C. NanoString expression graphs of atherosclerosis-related 
inflammatory genes that changed more than two-fold with TERT deletion. Data 
are presented as fold increase relative to untreated cells. Values are mean± 
SEM.  
105 
 
 
Figure 4.8 Gene Ontology Enrichment Analysis of TERT-Target Genes. 
LPS-induced inflammatory genes changed more than 1.5 fold by TERT 
deletion are included in gene ontology (GO) biological process enrichment 
analysis. Enrichment analysis was performed using the Gene Ontology 
Consortium (http://geneontology.org/page/go-enrichment-analysis) based on 
biological process terms. P-value of every enriched biological process is 
indicated at the end of each column. IL-1: interleukin-1; interferon-gamma: 
IFNɣ; TNF: tumor necrosis factor; lipopolysaccharide: LPS: 
lipopolysaccharides; ERK: extracellular signal–regulated kinases. 
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Figure 4.9 TERT Activates STAT3 Signaling Pathway. 
A. Inhibition of STAT3 phosphorylation in TERT-deficient BMDM. G1TERT-/- and 
G1TERT+/+ BMDM were stimulated with 100ng/ml LPS for 1 hour; P-STAT3 and 
total STAT3 protein expression were detected by Western blot analysis. B. 
Enhanced STAT3 phosphorylation in the BMDM overexpressing TERT (TERT-
Tg). TERT-Tg and TERT+/+ BMDM were treated with 100ng/ml LPS for 1 hour; 
P-STAT3 and total STAT3 protein expression were detected by Western blot 
analysis. C-D. Increased STAT3 phosphorylation in HEK 293 cells with TERT 
overexpression. HEK 293 cells were transfected with plasmids that overexpress 
TERT. 24 hours after transfection, cells were treated with 1µg/ml LPS (C) or 
10ng/ml IL-6 (D) for 30 minutes before whole cell lysates were collected. P-
STAT3 and total STAT3 protein expression were detected by Western blot 
analysis.  
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Figure 4.10 Reduced STAT3 Activation within the Macrophages in the 
Atherosclerotic Lesions of LDLr-/- Mice with Bone Marrow Deletion of 
TERT 
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A. Representative images of the p-STAT3 and CD68 co-staining in the sections 
of aortic roots from LDLr-/- mice transplanted with TERT+/+ or TERT-/- bone 
marrow. Sections were stained for macrophage marker CD68 (green), p-STAT3 
(red), and counterstained with 4′, 6-diamidino-2-phenylindole (DAPI) to visualize 
nuclei (blue). The merged images show the composite staining. The co-
localization of CD68 and p-STAT3 immunoreactivity is yellow. Scale bar, 100µm. 
B. Quantification of p-STAT3-positive macrophages within the aortic 
atherosclerotic lesion. The area of p-STAT3 positive macrophages within the 
atherosclerotic lesions was counted from three equally distributed sites on each 
segment using software ImageJ. Results are presented as mean ± SEM 
(*P<0.05 vs. BMT TERT+/+LDLr-/-). 
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5 CHAPTER FIVE 
General Discussion 
5.1 Summary 
Telomerase reverse transcriptase (TERT) is the catalytic subunit of 
telomerase and the limiting factor for enzymatic activity. Expression of TERT and 
telomerase activity is increased in atherosclerotic plaques. However, the role of 
TERT dysregulation during atherosclerosis formation remains unknown. 
The work herein first identified a multi-tiered regulation of TERT expression 
in VSMC through HDAC inhibition.  In VSMC treated with a small molecular HDAC 
inhibitor, the abundance of TERT transcript increased through transactivation of 
the TERT promoter. At the protein level, in contrast, HDAC inhibition accelerated 
the turnover of TERT towards degradation, which reduced overall telomerase 
activity and induced senescence. Furthermore, during vascular remodeling, TERT 
protein expression in the neointima was suppressed by HDAC inhibition. These 
data illustrate a differential regulation of TERT transcription and protein stability by 
HDAC inhibition. Moreover, the current study found that TERT deficiency reduces 
neointima formation following guidewire-induced arterial injury. Studies in SMC 
isolated from TERT-deficient and TERT overexpressing mice established that 
TERT is necessary and sufficient for cell proliferation without affecting telomere 
length. TERT deficiency induced cell cycle arrest at G1 phase without causing 
senescence albeit hyperphosphorylation of the retinoblastoma protein. This 
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proliferative arrest was associated with stable silencing of the E2F1-dependent S-
phase gene expression program which could not be reversed by ectopic 
overexpression of E2F1. Chromatin immunoprecipitation and accessibility assays 
revealed that TERT was recruited to chromatin regions containing E2F1 binding 
sites and facilitated the permissive histone modifications to allow the access of 
these locations to the transcription factor. These data indicate a promotional effect 
of TERT on SMC growth and neointima formation through epigenetic regulation of 
proliferative gene expression. Also, we investigated the function of TERT in 
macrophages during atherosclerosis formation. TERT expression was upregulated 
in activated macrophages during atherosclerosis formation. To study the role of 
TERT in this process, we crossbred TERT-deficient mice with LDL-receptor-
deficient (LDLr-/-) mice to generate first generation G1TERT-/-LDLr-/- offsprings, 
which were then intercrossed to obtain the third generation G3TERT-/-LDLr-/- 
mice. G1TERT-/-LDLr-/- mice exhibited no telomere shortening while severe 
telomere attrition was evident in G3TERT-/-LDLr-/- mice. When fed an atherogenic 
diet, G1TERT-/-LDLr-/- and G3TERT-/-LDLr-/- mice were both protected from 
atherosclerosis formation compared to their wild-type controls, indicating that 
genetic TERT-deletion prevents atherosclerosis, and formation of the disease is 
not affected by telomere attrition. Similarly, atherosclerotic development was 
decreased in chimeric LDLr-/- mice with stem cell deletion of TERT generated by 
bone marrow transplantation. TERT deficiency reduced the accumulation of 
macrophages in atherosclerotic lesions and inhibited the expression of 
proinflammatory cytokines, including CXC1/2/3, CCL3, CCL5, CCL21, CCR7, IL-
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6, and IL-1α. Gene ontology (GO) enrichment analysis of inflammatory genes 
altered by TERT deletion identified an overrepresentation of STAT3-dependent, 
which was confirmed by western blotting showing a decreased tyrosine 
phosphorylation of the STAT3 protein in TERT-deficient BMDM. These findings 
suggest that the protective effect of TERT deletion on atherosclerosis formation is 
likely a result of suppressed STAT3 signaling in macrophages, which silences the 
expression of a variety of proinflammatory cytokines. 
In conclusion, the current study identifies that TERT dysregulation within 
atherosclerotic plaques plays a causative role in atherosclerosis and injury-
induced neointima formation by promoting VSMC proliferation and macrophage 
inflammatory response. These findings identify a novel mechanism by which TERT 
might exacerbate pathological vascular remodeling under diseased conditions, 
which may provide a new therapeutic target. 
5.2 TERT Dysregulation During Vascular Remodeling 
5.2.1 TERT Expression Is Up-Regulated in the VSMC and Macrophages 
During Vascular Remodeling 
Telomeres get shortened with each cell division due to the “end replication 
problem”42. Therefore, the inverse relationship between telomere attrition and age 
makes telomere length to be proposed as a candidate biomarker of aging68, which 
is a major risk factor for atherosclerosis179. Consequently, leukocyte telomere 
attrition is suggested to correlate with vascular aging and cardiovascular events, 
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although the clinical association has not been consistent68. Furthermore, telomere 
length measured in peripheral leukocytes is not a surrogate marker for other 
tissues180. In line with this concept is Huzen’s finding that atherosclerosis patients 
had shorter leukocyte telomeres, but longer plaque telomeres that are related to 
plaque characteristics and development of restenosis following endarterectomy69. 
Therefore, the relationship between short leukocyte telomere length and 
atherosclerosis severity is inconclusive, and telomere integrity in local tissue may 
change differently from that of peripheral blood cells.  
Telomerase, an enzyme with its RNA template and reverse transcriptase, 
is the primary mechanism to prevent telomere erosion by synthesizing telomeric 
DNA25.  Telomerase activity and the expression of its catalytic subunit TERT are 
suppressed in differentiated cells29, 181. In line with this concept, expression of 
TERT and telomerase activity was found to be negligible in the normal vasculature. 
In the pathogenic vascular remodeling process preceding atherosclerosis and 
injury-induced neointima formation, however, TERT expression and telomerase 
was reactivated30, 31, 71. Our findings are consistent with an earlier study in which 
an increased TERT expression and telomerase activity were identified in the aorta 
of hypertension132. Data published by Matthews et al. also noted that TERT 
expression was readily detectable in lesional macrophages78. Similarly, 
neutrophils isolated from coronary artery plaques of patients with unstable angina 
was found to have abnormal telomerase activity70.  In contrast, EC in the aortic 
wall during aneurysm formation182 and VSMC in the atherosclerotic fibrous cap78 
were thought to express low levels of TERT rendering the telomerase inert. 
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However, a technical drawback was acknowledged in these two studies, that both 
measured TERT and telomerase expression using immunohistochemistry 
staining, which only provides the semi-quantitative assessment thus presents a 
risk of experimental bias. With repeated analysis in three different mouse models, 
our group provides compelling evidence for the reactivation of telomerase and 
TERT expression in the artery during vascular remodeling. 
5.2.2 Multi-Layer Control of TERT Expression During Vascular Remodeling 
Transcriptional control constitutes the primary mechanism of regulation of 
TERT expression183. Our previous studies observed a profound induction of TERT 
expression and telomerase activity in the neointima following vascular injury 
mediated by Ets-1 or E2F1 dependent transactivation of the TERT promoter30, 31; 
besides, a similar change in TERT expression and telomerase activity was 
detected in atherosclerotic lesional macrophages as a result of NF-kB signaling71. 
This early research from our group indicates that pro-atherogenic mediators 
upregulate TERT transcription through promoter activation. 
 In addition to transcriptional regulation, TERT expression is also subject to 
modulation via post-transcriptional, post-translational modifications, as well as 
epigenetic mechanisms27. In the current study, we illustrate a differential control at 
the transcript versus protein levels of TERT expression by HDAC inhibition. 
Quiescent somatic cells epigenetically silence the TERT promoter activity by 
histone deacetylation38, an effect that is reversed during malignant cell growth due 
to HDAC sequestration41. Our observation of enhanced TERT promoter activity 
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upon HDAC inhibition is consistent with several prior studies38, 39, 111. However, we 
also noticed a decrease in the abundance of TERT protein and telomerase activity 
due to enhanced degradation of the TERT protein. The two-stage control of TERT 
expression by HDAC inhibition might be a result of enhanced global acetylation of 
nonhistone proteins following HDAC inhibitor treatment. HDAC inhibitors have 
been shown to promote protein degradation through post-translational modification 
in addition to the classical epigenetic mechanism115, 116. Moreover, although TERT 
expression is primarily regulated at the transcriptional level, posttranslational 
modification and proteasome-mediated degradation of TERT have been reported 
to play a significant role in telomerase inactivation117, 118. Therefore, our findings 
support the notion that TERT expression is subject to a coordinated multi-layer 
control of expression, in which HDAC inhibitor-induced protein acetylation may 
modulate levels of epigenetic and post-translational regulation of TERT protein 
expression. 
5.3 TERT in Atherosclerosis Formation 
5.3.1 Telomere-Independent Function of TERT in Vascular Remodeling 
The mitogenic phenotype of VSMC triggers the intimal hyperplasia at the 
early stage of atherosclerosis3. In the present study, we illustrate a previously 
unrecognized epigenetic regulation of TERT over E2F1 target genes in 
proliferating VSMC. TERT associates with histone acetyltransferase P300 to open 
chromatin regions at E2F1 consensus sites and facilitates E2F1 target gene 
transcription to induce cell cycle progression. As macrophage-mediated 
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inflammation plays a fundamental role in all stages of disease from initiation 
through progression and, ultimately, the thrombotic complications of 
atherosclerosis, we continued to investigate the macrophage-specific function of 
TERT. Our data show that TERT deficiency suppresses atherosclerosis formation 
through silencing STAT3-regulatedinflammatory genes in macrophages. 
Moreover, preliminary results on the function of TERT in VSMC and macrophages 
were corroborated by similar findings from in vivo experiments in the early 
generation of TERT-deficient mice with normal telomere length, suggesting a 
telomere-independent function of TERT during vascular remodeling. In concert 
with these observations was our previous study that also documented that TERT-
deficient macrophages per se could prevent MMP-2 transcription and aortic 
aneurysm formation with no significant telomere erosion57. In support of our 
findings of this novel function of TERT, results from other groups show that TERT 
modulates the chromatin state184, interacts with DNA-modifying enzymes60, and 
activates a variety of genes regulating proliferation55, 152, 185, apoptosis46, 148, 186, 187, 
inflammation58, 86, 188, angiogenesis189, 190, and stem cell mobilization191, 192. 
Therefore, TERT may regulate cell function not only through canonic telomere 
elongation but also through non-canonical mechanisms that require further 
investigation.  
5.3.2 TERT Facilitates Chromatin Remodeling 
Using chromatin immunoprecipitation assays, we demonstrate that TERT 
promotes E2F1 target gene transcription by increasing chromatin accessibility 
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through p300-medaited histone acetylation. Other groups also identified that TERT 
modulates chromatin architecture through interaction with BRG1 (Brahma-related 
gene 1)60, 184, a subunit of chromatin remodeling complex SWI/SNF with ATPase 
activity. The model explains the synergistic effects of histone acetylation and ATP-
dependent chromatin remodeling complexes on transcriptional activation, during 
which additional chromatin remodeling complexes, including the SWI/SNF 
complex, are recruited to restructure the nucleosomes and expose the binding 
sites of transcriptional factors35. In line with this concept, accumulating evidence 
supports that the p300 coactivator interacts with the chromatin-modifying BRG1 
complex during transcriptional activation to stimulate histone acetylation193, 194. 
Specifically, Zhang et al. characterized a BAF (BRG1-associated factors)-
mediated interaction of p300 and BRG1 during transcriptional regulation195. 
Consistent with these findings, our observation of TERT binding to p300 may 
provide a mechanism by which TERT permits transcription of proliferative genes. 
Therefore, our current findings identify a novel role of TERT in the epigenetic 
regulation of VSMC proliferation. 
5.4 Future Study 
5.4.1 Define the Core Transcriptional Network of TERT During 
Atherosclerosis Formation 
Our study characterizes TERT as a transcriptional coactivator to generate 
permissive chromatin through association with p300 to promote histone H3 
acetylation.  Histone acetylation marks genes that are actively transcribed196. 
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Therefore, the binding of TERT to the enhancer-associated protein p300 supports 
that TERT serves as a bridge between the core transcriptional machinery and the 
functional regulatory elements during transcriptional activation. A similar 
mechanism of chromatin regulation has been described by the interaction between 
BRG1 and TERT to facilitate the transcription of Wnt target genes60. Furthermore, 
TERT has been shown to regulate transcription via an association with the 
transcriptional machinery. For example, TERT increases RNA pol III binding to 
target genomic regions197; TERT physically binds to p65 and affects genome-wide 
p65 occupancy of target chromatin58. Furthermore, many studies have implied that 
TERT binds to various promoter regions and activates target gene transcription. 
For example, TERT stimulates RNA polymerase I transcription and enhances 
ribosomal biogenesis198. Based on these findings, we hypothesize that TERT is 
involved in a transcriptional network that ultimately controls essential cellular 
functions, including proliferation, inflammation, apoptosis, and DNA damage 
response pathways. Given that TERT is highly expressed and exhibits potent 
telomerase activity within the atherosclerotic lesions, it will be important to 
understand related mechanisms by which TERT regulates cellular functions and 
accelerates disease progression.   
5.4.2 Define the Pharmacological Application of TERT for Atherosclerosis 
Treatment   
A hallmark of atherosclerosis development and neointimal remodeling is 
aberrant VSMC proliferation2, which can be effectively suppressed by HDAC 
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inhibitors101. HDAC inhibitors have been characterized as a unique category of 
anti-cancer drugs with four HDAC inhibitors approved by the United States Food 
and Drug Administration. HDAC inhibitors target TERT expression in cancer cells40 
121. Our current study further demonstrates a novel mechanism underlying the anti-
mitotic efficacy of HDAC inhibitors during neointima formation involving the 
suppression of TERT expression. Moreover, TERT dysregulation within the arterial 
wall contributes to atherosclerosis and neointima formation by promoting VSMC 
proliferation and macrophage inflammatory responses. These findings prompt an 
intriguing question:  Is TERT a reliable pharmacological target for atherosclerosis 
therapy? There are a variety of telomerase-inhibiting compounds under 
investigation for cancer therapy since most cancer cells exhibit high telomerase 
activity compared to normal somatic cells. However, there is currently no TERT 
targeting compound suitable for selectively targeting tumor cells without affecting 
the normal stem cell population, highlighting the importance of cell-specific 
targeting for future pharmacological development.  
In summary, the current study highlights an aberrant over-expression of 
TERT within atherosclerotic lesions and a novel role of TERT in VSMC mitosis and 
macrophage inflammation. However, in order to design potent TERT-targeting 
therapeutics for vascular diseases and avoid potential side effects, a gap for future 
development remains. In particular, understanding mechanisms of gene regulation 
by TERT and pathways of cell-specific targeting of TERT will constitute important 
avenues for future research.   
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Figure 5.1 Proposed TERT Function Over Transcription Regulation. 
TERT plays a role in bridging the core transcriptional machinery to the functional 
regulatory elements during transcriptional activation. A, TERT acts as a 
transcriptional factor binding to the DNA motif to activate target promoters. The 
nucleotides in color are the presumed sequence motif of TERT in hESC-1 cells 
based on genome-wide ChIP-seq results197. B, TERT recruits transcriptional 
coactivators to the core machinery thus enhancing transcriptional efficiency. 
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APPENDICES 
Figure A.1 A, TERT depletion using siRNA-mediated knock-down. Human 
coronary artery SMC were transfected with TERT siRNA or scrambled control, 
serum deprived for 24 hours, and stimulated with FBS for 48 hours. TERT 
expression was analyzed by Western Blotting. Co-hybridization for GAPDH was 
used to control for equal protein loading. B-C, Adenovirus-mediated 
overexpression of TERT in human coronary artery SMC. Cells were transduced 
for the indicated time points with 30 PFU of adenoviral constructs and analyzed for 
TERT expression by Western Blotting (B). Transduction efficiency of co-expressed 
GFP was confirmed by fluorescent microscopy at 50 PFU (C). The autoradiograms 
and images shown are representative of at least three independently performed 
experiments using different cell preparations. (D) TERT depletion using a lentiviral 
vector expressing TERT shRNA. Human coronary artery SMC were transduced 
with lentiviral vector expressing TERT shRNA (shTERT) or nontargeting control 
(shCTL) for 24 hours. mRNA expression of TERT was analyzed 48 hours after 
transduction by quantitative real-time PCR and normalized to transcript levels of 
the housekeeping gene TBP. Values are mean ± SEM (*P<0.05 versus shCTL). 
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Figure A.2 Telomere lengths of SMC isolated from G1TERT+/+, G1TERT- /- and 
G3TERT-/- mice. Quantification of telomere lengths in G1TERT+/+, G1TERT-/- 
and G3TERT-/- SMC using real-time PCR (n=3 mice per group). Data are 
presented as fold change relative to 36B4 (mean ± SEM, *P P<0.05 versus 
G1TERT+/+).  
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Figure A.3. A, G1TERT+/+ and G1TERT-/- SMC were stained for senescence-
associated b-galactosidase activity (objective magnification, x20). The images 
shown are representative of three independently performed experiments using 
different cell preparations. B, Transcript levels of p16, p21, p53, p27, CDK4, CDK6, 
E2F2, E2F3, and E2F4 in G1TERT+/+ and G1TERT-/- SMC. mRNA expression 
levels of the indicated genes were analyzed by real-time RT-PCR and normalized 
to transcript levels of the housekeeping gene transcription factor TFIIB. Data are 
presented as mean ± SEM, (n=4/group). 
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Figure A.4 TERT deletion does not affect E2F1 expression in SMC. Western 
blotting for E2F1 expression in whole cell lysates isolated from quiescent SMC (- 
FBS) stimulated with FBS (+ FBS). Co-hybridization for GAPDH was used to 
control for equal protein loading. The autoradiogram shown is representative of 
three independently performed experiments using different cell preparations. 
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Figure A.5 TERT deletion does not affect E2F1 expression in SMC. Western 
blotting for E2F1 expression in whole cell lysates isolated from quiescent SMC (- 
FBS) stimulated with FBS (+ FBS). Co-hybridization for GAPDH was used to 
control for equal protein loading. The autoradiogram shown is representative of 
three independently performed experiments using different cell preparations. 
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Figure A.6 TERT binding is dependent on the presence of the E2F1 binding site 
in the MCM7 promoter. Chromatin upstream of the E2F1 promoter sequence was 
not immunoprecipitated by the TERT antibody. Data are presented as mean ± 
SEM (#P<0.05 versus quiescent shCTL, *P<0.05 versus FBS treated shCTL).  
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Table I: Primers used in this study 
Name Use Sequence 
Murine MCM7 RT-PCR 
F: 5’-GGCACAGGGCTTACTCTCAG-3’ 
R: 5’-AGGAGACTGGTCCACACCAC-3’ 
Murine Cyclin A RT-PCR 
F: 5’-CTTGCTGCGGGTAAAGAGAC-3’ 
R: 5’-CGCAGCAGAAGCTCAAGGC-3’ 
Murine PCNA RT-PCR 
F: 5’-TTGGAATCCCAGAACAGGAG-3’ 
R: 5’-ATTGCCAAGCTCTCCACTTG-3’ 
Human MCM7 RT-PCR 
F: 5’-TGTGGGGCAGAGACCTAC-3’ 
R: 5’-CTGGGCAATCCTTGTGTT-3’ 
Murine P53 RT-PCR 
F: 5’-CCTCTGAGCCAGGAGACATTTTC-3’ 
R: 5’-AAGCCCAGGTGGAAGCCATAGTTG-3’ 
Murine Rb RT-PCR 
F: 5’-CCTTGAACCTGCTTGTCCTC-3’ 
R: 5’-GGGCAAGGGAGGTAGATTTC-3’ 
Murine P16 RT-PCR 
F: 5’-CTTTGTGTACCGCTGGGAAC-3’ 
R: 5’-CGCTAGCATCGCTAGAAGTG-3’ 
Murine P21 RT-PCR 
F: 5’-GTACTTCCTCTGCCCTGCTGC-3’ 
R:5’-GCTTGGAGTGATAGAAATGGTCAGG-3’ 
Murine P27 RT-PCR 
F: 5’-GCCGGGATATGGAAGAAG-3’ 
R:5’-ATGCCGGTCCTCAGAGTT-3’ 
Murine CDK4 RT-PCR 
F: 5’-GCTGCCACTCGATATGAACC-3’ 
R: 5’-CCTTAACAAGGCCACCTCAC-3’ 
Murine CDK6 RT-PCR 
F: 5’-GAGAAGGACAGCCTGAGTCG-3’ 
R: 5’-CCTCACTGGTCTGCACTCG-3’ 
Murine E2F2 RT-PCR 
F: 5’-ACGGCGCAACCTACAAAGAG-3’ 
R: 5’-GTCTGCGTGTAAAGCGAAGT-3’ 
Murine E2F3 RT-PCR F: 5’-AAACGCGGTATGATACGTCCC-3’ 
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R: 5’-CCATCAGGAGACTGGCTCAG-3’ 
Murine E2F4 RT-PCR 
F: 5’-CTCACCACCAAGTTCGTGTC-3’ 
R: 5’-TCTCGATCAGACCGATGCCTT-3’ 
Murine TFIIB RT-PCR 
F: 5’-CTCTCCCAAGAGTCACATGTCC-3’ 
R: 5’-CAATAACTCGGTCCCCTACAAC-3’ 
Human TBP RT-PCR 
F: 5’-GGAGAGTTCTGGGATTGTACCGC-3’ 
R: 5’-ATATTCGGCGTTTCGGGCAC-3’ 
E2F1 target sites 
within the murine 
MCM7 promoter 
ChIP 
F: 5’-GCTTTAAGAAACACTCCTCCCACAC-3’ 
R: 5’-GCCAGCCCCTAACTTTAACCAATCAA-3’ 
E2F1 target sites 
within the murine 
PCNA promoter 
ChIP 
F:5’-CCTCCCAGGCTCCTACCC-3’ 
R: 5’-GGCCTACAGCGACAACTACC-3’ 
E2F1 target sites 
within the murine 
Cyclin A promoter 
ChIP 
F:5’-CCACTGAGCAGCAGAGATCGGC-3’ 
R: 5’-GGCGGGAGGAGCGTAGAGC-3’ 
Upstream sequence 
of E2F1 binding 
sites in the murine 
MCM7 promoter 
ChIP 
F: 5’-CACATTGCGTGAGATGGTTC-3’ 
R: 5’-GGTGGCCACAACCTTAGAAA-3’ 
Upstream sequence 
of E2F1 binding 
sites in the murine 
PCNA promoter 
ChIP 
F: 5’-CGGGTTCATCTTCAGCCTAA-3’ 
R: 5’- GCGTCGCTCTGAACTTTTCT-3’ 
Upstream sequence 
of E2F1 binding 
ChIP 
F: 5’-AGGACAATTGGGACAGCATT-3’ 
R: 5’-CTAGGCAGGAGCGTATGGAT-3’ 
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sites in the murine 
Cyclin A promoter 
E2F1 target sites 
within the human 
MCM7 promoter 
ChIP 
F: 5’- ATGTTGGCCAGGCTGATTTC -3’ 
R: 5’- CTCCCAGGACTGGTTCATTG-3’ 
E2F1 target sites in 
the human PCNA 
promoter 
ChIP 
F: 5’- CTGGCTGCTGCGCGA-3’ 
R: 5’- CACCACCCGCTTTGTGACT-3’ 
E2F1 target sites in 
the human Cyclin A 
promoter 
ChIP 
F:5’-TCACCTGGCTTGTCAGTCAC-3’ 
R:5’-GACAGAGCTGGGGCTTGG-3’ 
Upstream sequence 
of E2F1 binding 
sites in  the human 
MCM7 promoter 
ChIP 
F: 5’-GTAGAGGCGGAGTTTCACCA-3’ 
R: 5’-CTCCCAGGACTGGTTCATTG-3’ 
Upstream sequence 
of E2F1 binding 
sites in the human 
PCNA promoter 
ChIP 
F: 5’-TGTGATGCTATGTTTTAAAGAGGTACTGA-3’ 
R: 5’- AATTTTATGCCACGTACATCTTTTTATC-3’ 
Upstream sequence 
of E2F1 binding 
sites in the human 
Cyclin A promoter 
ChIP 
F: 5’-CGCTTTCATTGGTCCATTTC-3’ 
R: 5’-CCGGCCAAAGAATAGTCGTA-3’ 
E2F1 binding sites 
in the murine 
MCM7 promoter 
(-346 to -176) 
ChART 
PCR 
F: 5’-GCTTTAAGAAACACTCCTCCCACAC-3’ 
R: 5’-GCCAGCCCCTAACTTTAACCAATCAA-3’ 
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upstream sequence 
of the murine 
MCM7 promoter 
( -620 to -513)
ChART 
PCR 
F:5’-ACATCACGACCACCACTGTC-3’  
R: 5’-GGGGTAGGGTAGCTGGGTAG-3’ 
Telomere 
Telomere 
Length 
Analysis 
tel 1: 
5’-GTTTTTGAGGGTGAGGGTGAGGGTGAGGGTGAGGGT-3’ 
tel 2: 
5’-TCCCGACTATCCCTATCCCTATCCCTATCCCTATCCCTA-3’ 
36B4 
Telomere 
Length 
Analysis 
F: 5’-CAACCCAGCTCTGGAGAAAC-3’ 
R: 5’-AAGCCTGGAAGAAGGAGGTC-3’ 
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